

Inflammation in prostate carcinogenesis

Nature Reviews Cancer

7, 256-269

DOI: [10.1038/nrc2090](https://doi.org/10.1038/nrc2090)

Citation Report

#	ARTICLE	IF	CITATIONS
1	P-selectin. Expert Opinion on Therapeutic Targets, 2007, 11, 1103-1117.	1.5	80
2	Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: focus on clinical data. Expert Opinion on Investigational Drugs, 2007, 16, 1841-1849.	1.9	2
3	Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis, 2007, 29, 568-572.	1.3	29
4	Uteroglobulin: A Steroid-Inducible Immunomodulatory Protein That Founded the Secretoglobulin Superfamily. Endocrine Reviews, 2007, 28, 707-725.	8.9	131
5	Biomarkers for the Early Detection of Cancer<subtitle>An Inflammatory Concept</subtitle>. Archives of Internal Medicine, 2007, 167, 1822.	4.3	7
6	Cholesterol Fractions and Apolipoproteins as Risk Factors for Heart Disease Mortality in Older Men. Archives of Internal Medicine, 2007, 167, 1373.	4.3	67
7	Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2213-2217.	1.1	136
8	Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. Journal of Molecular Endocrinology, 2007, 39, 183-188.	1.1	73
9	Viral Encounters with 2â€™,5â€™-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response. Journal of Virology, 2007, 81, 12720-12729.	1.5	522
10	Sex Hormones Induce Direct Epithelial and Inflammation-Mediated Oxidative/Nitrosative Stress That Favors Prostatic Carcinogenesis in the Noble Rat. American Journal of Pathology, 2007, 171, 1334-1341.	1.9	45
11	Regulation of Cox-2 by Cyclic AMP Response Element Binding Protein in Prostate Cancer: Potential Role for Nexrutine. Neoplasia, 2007, 9, 893-899.	2.3	50
13	Tissue vaccines for cancer. Expert Review of Vaccines, 2007, 6, 925-937.	2.0	8
14	Genomic Signatures Associated with the Development, Progression, and Outcome of Prostate Cancer. Molecular Diagnosis and Therapy, 2007, 11, 345-354.	1.6	7
15	Current Immunotherapeutic Strategies in Prostate Cancer. Surgical Oncology Clinics of North America, 2007, 16, 861-871.	0.6	3
16	Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti-Inflammatory Activity. Journal of Bone and Mineral Research, 2007, 22, V74-V80.	3.1	56
17	Treating prostate cancer: a rationale for targeting local oestrogens. Nature Reviews Cancer, 2007, 7, 621-627.	12.8	102
18	Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes and Immunity, 2007, 8, 646-652.	2.2	81
19	Tollâ€™like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology. Immunology and Cell Biology, 2007, 85, 481-489.	1.0	79

#	ARTICLE	IF	CITATIONS
20	The antibody response to <i>Propionibacterium acnes</i> is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men. <i>BJU International</i> , 2007, 101, 070915222359007-???.	1.3	11
21	Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1776, 1-9.	3.3	15
22	Inflammation and Chronic Prostatic Diseases: Evidence for a Link?. <i>European Urology</i> , 2007, 52, 964-972.	0.9	159
23	Prostate cancer and chronic prostatitis. <i>Current Prostate Reports</i> , 2007, 5, 191-195.	0.1	0
24	Dietary interventions in prostate cancer. <i>Current Prostate Reports</i> , 2008, 6, 155-163.	0.1	0
25	Dietary interventions in prostate cancer. <i>Current Urology Reports</i> , 2008, 9, 217-225.	1.0	8
26	Inflammation and prostate cancer: A focus on infections. <i>Current Urology Reports</i> , 2008, 9, 243-249.	1.0	48
27	Prostate cancer and chronic prostatitis. <i>Current Urology Reports</i> , 2008, 9, 328-332.	1.0	27
28	Histone deacetylase regulation of immune gene expression in tumor cells. <i>Immunologic Research</i> , 2008, 40, 164-178.	1.3	43
29	A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. <i>Prostate</i> , 2008, 68, 306-320.	1.2	167
30	<i>TNF</i> polymorphisms and prostate cancer risk. <i>Prostate</i> , 2008, 68, 400-407.	1.2	42
31	Histopathological evidence for an association of inflammation with ductal pinâ€like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. <i>Prostate</i> , 2008, 68, 728-739.	1.2	31
32	Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. <i>Prostate</i> , 2008, 68, 766-772.	1.2	78
33	Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. <i>Prostate</i> , 2008, 68, 872-882.	1.2	51
34	Identification of candidate prostate cancer genes through comparative expressionâ€profiling of seminal vesicle. <i>Prostate</i> , 2008, 68, 1248-1256.	1.2	26
35	Oligomeric proanthocyanidin complexes (OPC) exert antiâ€proliferative and proâ€apoptotic effects on prostate cancer cells. <i>Prostate</i> , 2008, 68, 1647-1654.	1.2	27
36	Selenium and the prevention of prostate and colorectal cancer. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 1261-1272.	1.5	93
37	Prostateâ€specific antigen levels in relation to consumption of nonsteroidal antiâ€inflammatory drugs and acetaminophen. <i>Cancer</i> , 2008, 113, 2053-2057.	2.0	45

#	ARTICLE	IF	CITATIONS
38	Joint effects of inflammation and androgen metabolism on prostate cancer severity. <i>International Journal of Cancer</i> , 2008, 123, 1385-1389.	2.3	19
39	Genetic variation in the toll-like receptor gene cluster (<i>TLR10</i> , <i>TLR1</i> , <i>TLR6</i>) and prostate cancer risk. <i>International Journal of Cancer</i> , 2008, 123, 2644-2650.	2.3	79
40	Inflammation as the primary aetiological agent of human prostate cancer: A stem cell connection?. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 931-939.	1.2	38
41	Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. <i>Biotechnology and Bioengineering</i> , 2008, 100, 567-578.	1.7	46
42	Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. <i>Apmis</i> , 2008, 116, 491-498.	0.9	23
43	Sirolimus Reduces the Incidence and Progression of UVB-Induced Skin Cancer in SKH Mice even with Co-administration of Cyclosporine A. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2467-2473.	0.3	54
44	Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. <i>Modern Pathology</i> , 2008, 21, 1156-1167.	2.9	363
45	Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. <i>Nature Biotechnology</i> , 2008, 26, 1373-1378.	9.4	507
46	Polymorphisms in Toll-like receptor genes and risk of cancer. <i>Oncogene</i> , 2008, 27, 244-252.	2.6	218
47	Mycoplasma infection suppresses p53, activates NF- κ B and cooperates with oncogenic Ras in rodent fibroblast transformation. <i>Oncogene</i> , 2008, 27, 4521-4531.	2.6	69
48	TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. <i>Oncogene</i> , 2008, 27, 5348-5353.	2.6	218
49	The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. <i>Oncogene</i> , 2008, 27, 4353-4362.	2.6	167
50	Hypothesis: "Ultraviolet B Irradiance and Vitamin D Reduce the Risk of Viral Infections and thus Their Sequelae, Including Autoimmune Diseases and some Cancers". <i>Photochemistry and Photobiology</i> , 2008, 84, 356-365.	1.3	70
51	Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. <i>BJU International</i> , 2008, 101, 1519-1523.	1.3	35
52	Malignant lesions in the ventral prostate of alloxan-induced diabetic rats. <i>International Journal of Experimental Pathology</i> , 2008, 89, 276-283.	0.6	21
53	The effect of dietary supplementation with limonene or myo-inositol on the induction of neoplasia and matrix metalloproteinase and plasminogen activator activities in accessory sex organs of male <i>Lobund</i> "Wistar" rats. <i>Experimental and Molecular Pathology</i> , 2008, 85, 83-89.	0.9	11
54	Prostatic preneoplasia and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2008, 1785, 156-181.	3.3	23
55	Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. <i>Cancer Detection and Prevention</i> , 2008, 32, 23-32.	2.1	71

#	ARTICLE	IF	CITATIONS
56	Impact of stress and mast cells on brain metastases. <i>Journal of Neuroimmunology</i> , 2008, 205, 1-7.	1.1	54
57	PGE2 and LTB4 tissue levels in benign and cancerous prostates. <i>Prostaglandins and Other Lipid Mediators</i> , 2008, 87, 14-19.	1.0	48
58	Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. <i>BMC Cancer</i> , 2008, 8, 382.	1.1	59
59	Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo. <i>Retrovirology</i> , 2008, 5, 119.	0.9	26
60	Immunosenescence and Immunogenetics of Human Longevity. <i>NeuroImmunoModulation</i> , 2008, 15, 224-240.	0.9	165
62	The Malignant Phenotype of Breast Cancer Cells Is Reduced by COX-2 Silencing. <i>Neoplasia</i> , 2008, 10, 1163-1169.	2.3	20
64	Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing. <i>Clinical Cancer Research</i> , 2008, 14, 3254-3261.	3.2	367
65	Nrf2 signaling: An adaptive response pathway for protection against environmental toxic insults. <i>Mutation Research - Reviews in Mutation Research</i> , 2008, 659, 31-39.	2.4	459
66	Proliferative inflammatory atrophy: a background lesion of prostate cancer?. <i>Andrologia</i> , 2008, 40, 134-137.	1.0	36
67	Principles of Cancer Genetics. , 2008, , .		24
68	Prostate Cancer Stem Cells: A New Target for Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 2862-2870.	0.8	301
69	Differential Expression of Secretory Phospholipases A2 in Normal and Malignant Prostate Cell Lines: Regulation by Cytokines, Cell Signaling Pathways, and Epigenetic Mechanisms. <i>Neoplasia</i> , 2008, 10, 279-286.	2.3	43
70	Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 6162-6170.	0.4	661
71	BK Virus as a Cofactor in the Etiology of Prostate Cancer in Its Early Stages. <i>Journal of Virology</i> , 2008, 82, 2705-2714.	1.5	79
72	Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 146-155.	0.8	27
73	Integrins in prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2008, 15, 657-664.	1.6	154
74	Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men. <i>Cancer Research</i> , 2008, 68, 927-936.	0.4	438
75	Genetic Variants of the Copy Number Polymorphic α -Defensin Locus Are Associated with Sporadic Prostate Cancer. <i>Tumor Biology</i> , 2008, 29, 83-92.	0.8	24

#	ARTICLE	IF	CITATIONS
77	Statins and prostate cancer prevention: where we are now, and future directions. <i>Nature Reviews Urology</i> , 2008, 5, 376-387.	1.4	62
78	Delineation of <i>TMPRSS2-ERG</i> Splice Variants in Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4719-4725.	3.2	90
79	Ubiquitination by TOPORS Regulates the Prostate Tumor Suppressor NKX3.1. <i>Journal of Biological Chemistry</i> , 2008, 283, 4834-4840.	1.6	44
80	The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 11-25.	1.6	51
81	Long-term prognosis of the transient left ventricular dysfunction syndrome (Takotsubo) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582 T	2.9	129
82	Family-Based Samples Can Play an Important Role in Genetic Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2208-2214.	1.1	23
83	Genetic polymorphisms of human cytosol glutathioneS-transferases and prostate cancer. <i>Pharmacogenomics</i> , 2008, 9, 93-104.	0.6	44
84	Prostate cancer: genes, environment, immunity and the use of immunotherapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2008, 11, 230-236.	2.0	28
85	Targeted Overexpression of Vav3 Oncogene in Prostatic Epithelium Induces Nonbacterial Prostatitis and Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 6396-6406.	0.4	36
86	No Association between Common Chemokine and Chemokine Receptor Gene Variants and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3615-3617.	1.1	13
87	Inflammatory Cytokines Induce Phosphorylation and Ubiquitination of Prostate Suppressor Protein NKX3.1. <i>Cancer Research</i> , 2008, 68, 6896-6901.	0.4	59
88	Integration Site Preference of Xenotropic Murine Leukemia Virus-Related Virus, a New Human Retrovirus Associated with Prostate Cancer. <i>Journal of Virology</i> , 2008, 82, 9964-9977.	1.5	93
89	Dietary Cancer Chemopreventive Agents " Targeting Inflammation and Nrf2 Signaling Pathway. <i>Planta Medica</i> , 2008, 74, 1540-1547.	0.7	62
90	Interplay of Nuclear Factor- κ B and B-myb in the Negative Regulation of Androgen Receptor Expression by Tumor Necrosis Factor α . <i>Molecular Endocrinology</i> , 2008, 22, 273-286.	3.7	45
91	Prevention of Prostate Cancer: What We Know and Where We Are Going. <i>American Journal of Men's Health</i> , 2008, 2, 178-189.	0.7	7
93	Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Therapeutic Targets. <i>Advances in Anatomic Pathology</i> , 2008, 15, 319-331.	2.4	55
94	Inflammation, infection, and prostate cancer. <i>Current Opinion in Urology</i> , 2008, 18, 315-319.	0.9	87
96	Multi-faceted roles for CXC-chemokines in prostate cancer progression. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 4595.	3.0	50

#	ARTICLE	IF	CITATIONS
97	Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling, 2008, 6, nrs.06010.	1.0	129
98	Cholesterol and Cholesterol-Rich Membranes in Prostate Cancer: An Update. Tumori, 2008, 94, 633-639.	0.6	60
99	Low frequency of human papillomavirus detection in prostate tissue from individuals from Northern Brazil. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 665-667.	0.8	21
100	Hyaluronan Synthesis and Turnover in Prostate Cancer. , 2009, , 309-327.		0
101	Menthol Enhances an Antiproliferative Activity of 1 α ,25-Dihydroxyvitamin D3 in LNCaP Cells. Journal of Clinical Biochemistry and Nutrition, 2009, 44, 125-130.	0.6	21
102	Molecular Pathogenesis of Prostate Cancer: Somatic, Epigenetic, and Genetic Alterations. , 2009, , 489-500.		3
103	PTGS2 \rightarrow G>C and prostate cancer risk: a population-based nested case \rightarrow control study (ProtecT) and a systematic review with meta-analysis. Prostate Cancer and Prostatic Diseases, 2009, 12, 296-300.	2.0	16
104	The Association of Bone Mineral Density with Prostate Cancer Risk in the Osteoporotic Fractures in Men (MrOS) Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 148-154.	1.1	20
105	Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3443-3448.	3.3	124
106	XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16351-16356.	3.3	255
107	Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models. Pharmacological Reviews, 2009, 61, 262-282.	7.1	118
108	Fibrils of Prostatic Acid Phosphatase Fragments Boost Infections with XMRV (Xenotropic Murine) Tj ETQq1 1 0.784314 rgBT /Overloc 1 Virology, 2009, 83, 6995-7003.	1.5	71
109	Endocrine-Immune-Paracrine Interactions in Prostate Cells as Targeted by Phytomedicines. Cancer Prevention Research, 2009, 2, 134-142.	0.7	9
110	Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermato-Endocrinology, 2009, 1, 7-11.	1.9	14
111	Inflammation, prostatitis, proliferative inflammatory atrophy: \rightarrow Fertile ground \rightarrow ™ for prostate cancer development?. Molecular Medicine Reports, 2009, 3, 3-12.	1.1	12
112	Benign Prostatic Hyperplasia: Does Lifestyle Play a Role?. Physician and Sportsmedicine, 2009, 37, 141-146.	1.0	16
113	Critical Role of Endogenous Heme Oxygenase 1 as a Tuner of the Invasive Potential of Prostate Cancer Cells. Molecular Cancer Research, 2009, 7, 1745-1755.	1.5	108
114	Macrophage Inhibitory Cytokine-1: Possible Bridge Molecule of Inflammation and Prostate Cancer. Cancer Research, 2009, 69, 2-5.	0.4	89

#	ARTICLE	IF	CITATIONS
115	Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk. <i>Clinical Cancer Research</i> , 2009, 15, 2559-2566.	3.2	126
116	Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. <i>Carcinogenesis</i> , 2009, 30, 698-705.	1.3	68
117	Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 808-815.	1.1	25
118	Epigenetic mechanisms in the biology of prostate cancer. <i>Seminars in Cancer Biology</i> , 2009, 19, 172-180.	4.3	66
119	Freund's vaccine adjuvant promotes Her2/Neu breast cancer. <i>BMC Cancer</i> , 2009, 9, 19.	1.1	1
120	AHR signaling in prostate growth, morphogenesis, and disease. <i>Biochemical Pharmacology</i> , 2009, 77, 566-576.	2.0	48
121	The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer. <i>European Urology</i> , 2009, 55, 533-542.	0.9	153
122	Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma <i>in vitro</i> and <i>in vivo</i> via cyclooxygenase-2 and apoptotic pathways. <i>International Journal of Cancer</i> , 2009, 124, 2200-2209.	2.3	77
123	Age-specific physical activity and prostate cancer risk among white men and black men. <i>Cancer</i> , 2009, 115, 5060-5070.	2.0	33
124	Glucosamine inhibits IL-1-mediated IL-8 production in prostate cancer cells by MAPK attenuation. <i>Journal of Cellular Biochemistry</i> , 2009, 108, 489-498.	1.2	30
125	Increased androgen receptor and remodeling in the prostatic stroma after the inhibition of 5 α -reductase and aromatase in gerbil ventral prostate. <i>Microscopy Research and Technique</i> , 2009, 72, 939-950.	1.2	13
126	C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. <i>Cancer Causes and Control</i> , 2009, 20, 1193-1203.	0.8	55
127	TLR4 Polymorphisms and Ageing: Implications for the Pathophysiology of Age-Related Diseases. <i>Journal of Clinical Immunology</i> , 2009, 29, 406-415.	2.0	112
128	IL-10 \sim 1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. <i>World Journal of Urology</i> , 2009, 27, 389-396.	1.2	24
129	Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1919-1933.	2.0	39
130	SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells. <i>Journal of Pathology</i> , 2009, 217, 389-397.	2.1	25
131	Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: Preventive effects of celecoxib. <i>Prostate</i> , 2009, 69, 133-141.	1.2	33
132	Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. <i>Prostate</i> , 2009, 69, 181-190.	1.2	48

#	ARTICLE	IF	CITATIONS
133	Association of <i>IL10</i> and Other immune response and obesity related genes with prostate cancer in CLUE II. <i>Prostate</i> , 2009, 69, 874-885.	1.2	117
134	Expression level and DNA methylation status of glutathione <i>S</i> -transferase genes in normal murine prostate and TRAMP tumors. <i>Prostate</i> , 2009, 69, 1312-1324.	1.2	28
135	Evidence for field cancerization of the prostate. <i>Prostate</i> , 2009, 69, 1470-1479.	1.2	126
136	Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. <i>Prostate</i> , 2009, 69, 1387-1397.	1.2	53
137	Human prostate-infiltrating CD8 ⁺ T lymphocytes are oligoclonal and PD-1 ⁺ . <i>Prostate</i> , 2009, 69, 1694-1703.	1.2	206
138	Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. <i>Journal of Developmental and Physical Disabilities</i> , 2009, 32, 399-410.	3.6	47
139	Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. <i>Journal of Developmental and Physical Disabilities</i> , 2010, 33, 475-488.	3.6	178
140	Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. <i>Cancer Gene Therapy</i> , 2009, 16, 217-226.	2.2	73
141	C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. <i>British Journal of Cancer</i> , 2009, 100, 1846-1851.	2.9	13
142	Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. <i>British Journal of Cancer</i> , 2009, 101, 1740-1748.	2.9	54
143	CCR5 Proinflammatory Allele in Prostate Cancer Risk. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 289-292.	1.8	27
144	Long-term effects of developmental exposure to di-n-butyl-phthalate (DBP) on rat prostate: Proliferative and inflammatory disorders and a possible role of androgens. <i>Toxicology</i> , 2009, 262, 215-223.	2.0	48
145	Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. <i>Clinical Biochemistry</i> , 2009, 42, 1228-1235.	0.8	108
146	Quantitative metabolic profiling of 21 endogenous corticosteroids in urine by liquid chromatography-triple quadrupole-mass spectrometry. <i>Analytica Chimica Acta</i> , 2009, 632, 101-108.	2.6	80
147	Toponome Mapping in Prostate Cancer: Detection of 2000 Cell Surface Protein Clusters in a Single Tissue Section and Cell Type Specific Annotation by Using a Three Symbol Code. <i>Journal of Proteome Research</i> , 2009, 8, 2696-2707.	1.8	36
148	Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. <i>Current Opinion in Pharmacology</i> , 2009, 9, 419-426.	1.7	64
149	Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. <i>Cancer Letters</i> , 2009, 276, 38-46.	3.2	53
150	Oxidative stress in prostate cancer. <i>Cancer Letters</i> , 2009, 282, 125-136.	3.2	412

#	ARTICLE	IF	CITATIONS
151	Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. <i>Cancer Letters</i> , 2009, 282, 167-176.	3.2	115
152	Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 33-38.	1.8	49
153	Is There Evidence for a Role of <i>Propionibacterium acnes</i> in Prostatic Disease?. <i>Urology</i> , 2009, 73, 220-224.	0.5	8
154	Chronic Periglandular Inflammation on Prostate Needle Biopsy Does Not Increase the Likelihood of Cancer on Subsequent Biopsy. <i>Urology</i> , 2009, 73, 845-849.	0.5	5
155	DHEA metabolism in prostate: For better or worse?. <i>Molecular and Cellular Endocrinology</i> , 2009, 301, 83-88.	1.6	25
156	Risk factors for prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 87-95.	1.4	112
159	Etiology, Epidemiology, and Natural History. <i>Urologic Clinics of North America</i> , 2009, 36, 403-415.	0.8	176
160	Inflammation and oxidative stress in vertebrate host-parasite systems. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2009, 364, 71-83.	1.8	254
161	Prospective Study of <i>Trichomonas vaginalis</i> Infection and Prostate Cancer Incidence and Mortality: Physicians' Health Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1406-1411.	3.0	162
162	Gamma Tocopherol Upregulates the Expression of 15-S-HETE and Induces Growth Arrest Through a PPAR Gamma-Dependent Mechanism in PC-3 Human Prostate Cancer Cells. <i>Nutrition and Cancer</i> , 2009, 61, 649-662.	0.9	39
163	Omega-3 Fatty Acids, Genetic Variants in COX-2 and Prostate Cancer. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2009, 2, 149-158.	1.8	32
164	Lipoxin A ₄ inhibited hepatocyte growth factor-induced invasion of human hepatoma cells. <i>Hepatology Research</i> , 2009, 39, 921-930.	1.8	25
165	Loss of NADPH Quinone Oxidoreductase in the Prostate and Enhanced Serum Levels of Cytokine-Induced Neutrophil Chemoattractant CXCL1 in Hormone-Stimulated Noble Rats: Potential Role in Prostatic Intraepithelial Neoplasia Development. <i>Translational Oncology</i> , 2009, 2, 65-72.	1.7	2
166	IL-1 Induces IGF-Dependent Epithelial Proliferation in Prostate Development and Reactive Hyperplasia. <i>Science Signaling</i> , 2009, 2, ra49.	1.6	47
167	Targeted Delivery of Anti-Inflammatory Agents to Tumors. <i>Current Pharmaceutical Design</i> , 2009, 15, 1825-1843.	0.9	13
168	A Pilot Study on Prostate Cancer Risk and Pro-Inflammatory Genotypes: Pathophysiology and Therapeutic Implications. <i>Current Pharmaceutical Design</i> , 2010, 16, 718-724.	0.9	37
169	Xenotropic murine leukemia virus-related virus: current research, disease associations and therapeutic opportunities. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 377-384.	0.2	1
170	Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. <i>Future Oncology</i> , 2010, 6, 1289-1311.	1.1	59

#	ARTICLE	IF	CITATIONS
173	Expression of estrogen alpha and beta receptors in prostate cancer and hyperplasia: Immunohistochemical analysis. <i>African Journal of Urology</i> , 2010, 16, 79-87.	0.1	5
174	Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease. <i>Immunologic Research</i> , 2010, 48, 27-39.	1.3	6
175	Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. <i>Cancer Causes and Control</i> , 2010, 21, 1437-1444.	0.8	25
176	Mechanisms of intestinal inflammation and development of associated cancers: Lessons learned from mouse models. <i>Mutation Research - Reviews in Mutation Research</i> , 2010, 705, 40-59.	2.4	91
177	Propionibacterium acnes infection induces upregulation of inflammatory genes and cytokine secretion in prostate epithelial cells. <i>BMC Microbiology</i> , 2010, 10, 126.	1.3	35
178	Identification of viral infections in the prostate and evaluation of their association with cancer. <i>BMC Cancer</i> , 2010, 10, 326.	1.1	81
179	The 4q27 locus and prostate cancer risk. <i>BMC Cancer</i> , 2010, 10, 69.	1.1	7
180	A Transcriptional Signature and Common Gene Networks Link Cancer with Lipid Metabolism and Diverse Human Diseases. <i>Cancer Cell</i> , 2010, 17, 348-361.	7.7	309
181	TGF- β 1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. <i>Cellular Signalling</i> , 2010, 22, 1734-1744.	1.7	25
182	Association between antibiotic use and risk of prostate cancer. <i>International Journal of Cancer</i> , 2010, 127, 952-960.	2.3	17
183	Global levels of histone modifications predict prostate cancer recurrence. <i>Prostate</i> , 2010, 70, 61-69.	1.2	194
184	CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. <i>Prostate</i> , 2010, 70, 433-442.	1.2	98
185	Acute inflammation promotes early cellular stimulation of the epithelial and stromal compartments of the rat prostate. <i>Prostate</i> , 2010, 70, 1153-1165.	1.2	25
186	Eightplex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. <i>Prostate</i> , 2010, 70, 1313-1332.	1.2	46
187	Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. <i>Prostate</i> , 2010, 70, 1622-1627.	1.2	22
188	Distribution of Foxp3, CD4 and CD8 positive lymphocytic cells in benign and malignant prostate tissue. <i>Apmis</i> , 2010, 118, 360-365.	0.9	31
189	Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. <i>FEBS Journal</i> , 2010, 277, 4578-4590.	2.2	115
190	Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. <i>Cancer Science</i> , 2010, 101, 1570-1573.	1.7	21

#	ARTICLE	IF	CITATIONS
191	Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. <i>Cancer Science</i> , 2010, 101, 1947-1954.	1.7	145
192	Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. <i>Histopathology</i> , 2010, 57, 384-394.	1.6	20
193	Potential carcinogenic effects of cigarette smoke and Swedish moist snuff on pancreas: a study using a transgenic mouse model of chronic pancreatitis. <i>Laboratory Investigation</i> , 2010, 90, 426-435.	1.7	10
194	Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. <i>Nature Genetics</i> , 2010, 42, 668-675.	9.4	539
195	On the origin of prostate fusion oncogenes. <i>Nature Genetics</i> , 2010, 42, 647-648.	9.4	6
196	Variation across the allele frequency spectrum. <i>Nature Genetics</i> , 2010, 42, 648-650.	9.4	23
197	Prostate cancer as a model for tumour immunotherapy. <i>Nature Reviews Immunology</i> , 2010, 10, 580-593.	10.6	314
198	Inflammation targets specific organs for cancer in carriers of BRCA1/2 pathway mutations. <i>Nature Precedings</i> , 2010, , .	0.1	1
199	Genitourinary Infectious Disease Pathology. , 2010, , 403-441.		0
200	Inflammatory Genetic Markers of Prostate Cancer Risk. <i>Cancers</i> , 2010, 2, 1198-1220.	1.7	9
201	Prostatitis, Sexually Transmitted Diseases, and Prostate Cancer: The California Men's Health Study. <i>PLoS ONE</i> , 2010, 5, e8736.	1.1	109
202	The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment. <i>PLoS ONE</i> , 2010, 5, e12501.	1.1	104
203	Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of Cholesterol. <i>PLoS ONE</i> , 2010, 5, e14175.	1.1	135
204	LKB1/PEA3/Np63 Pathway Regulates PTGS-2 (COX-2) Transcription in Lung Cancer Cells Upon Cigarette Smoke Exposure. <i>Oxidative Medicine and Cellular Longevity</i> , 2010, 3, 317-324.	1.9	18
205	Molecular Pathogenesis of Prostate Cancer: Somatic, Epigenetic, and Genetic Alterations. , 2010, , 335-340.		0
206	Identification of EP4 as a Potential Target for the Treatment of Castration-Resistant Prostate Cancer Using a Novel Xenograft Model. <i>Cancer Research</i> , 2010, 70, 1606-1615.	0.4	82
207	Role of Bacteria in Oncogenesis. <i>Clinical Microbiology Reviews</i> , 2010, 23, 837-857.	5.7	149
208	Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. <i>Endocrine-Related Cancer</i> , 2010, 17, R19-R38.	1.6	117

#	ARTICLE	IF	CITATIONS
209	Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk. <i>Carcinogenesis</i> , 2010, 31, 1748-1754.	1.3	38
210	Sequence Variants in the TLR4 and TLR6-1-10 Genes and Prostate Cancer Risk. Results Based on Pooled Analysis from Three Independent Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 873-876.	1.1	32
212	Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels. <i>New England Journal of Medicine</i> , 2010, 363, 1621-1630.	13.9	263
213	Cancer and Inflammation: Promise for Biologic Therapy. <i>Journal of Immunotherapy</i> , 2010, 33, 335-351.	1.2	293
214	Rye Whole Grain and Bran Intake Compared with Refined Wheat Decreases Urinary C-Peptide, Plasma Insulin, and Prostate Specific Antigen in Men with Prostate Cancer ^{1&#x2013;3} . <i>Journal of Nutrition</i> , 2010, 140, 2180-2186.	1.3	65
215	Detection of Xenotropic Murine Leukemia Virus-Related Virus in Normal and Tumor Tissue of Patients from the Southern United States with Prostate Cancer Is Dependent on Specific Polymerase Chain Reaction Conditions. <i>Journal of Infectious Diseases</i> , 2010, 202, 1470-1477.	1.9	61
216	Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. <i>American Journal of Epidemiology</i> , 2010, 171, 571-582.	1.6	96
217	TLR Stimulation of Prostate Tumor Cells Induces Chemokine-Mediated Recruitment of Specific Immune Cell Types. <i>Journal of Immunology</i> , 2010, 184, 6658-6669.	0.4	68
218	Physical Activity and Genitourinary Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2010, 186, 43-71.	1.8	31
219	Nonsteroidal Anti-Inflammatory Drugs and Prostate Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3185-3188.	1.1	35
220	Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1. <i>Carcinogenesis</i> , 2010, 31, 820-826.	1.3	19
221	PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). <i>Carcinogenesis</i> , 2010, 31, 455-461.	1.3	68
223	MYC and Prostate Cancer. <i>Genes and Cancer</i> , 2010, 1, 617-628.	0.6	245
224	Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 311-315.	2.0	139
225	DNA Damage Recognition via Activated ATM and p53 Pathway in Nonproliferating Human Prostate Tissue. <i>Cancer Research</i> , 2010, 70, 8630-8641.	0.4	57
226	A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice. <i>Cancer Prevention Research</i> , 2010, 3, 1284-1291.	0.7	42
227	Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer. <i>Pharmaceuticals</i> , 2010, 3, 3127-3142.	1.7	3
228	Diet, Supplement Use, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. <i>American Journal of Epidemiology</i> , 2010, 172, 566-577.	1.6	139

#	ARTICLE	IF	CITATIONS
229	Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 753-764.	1.2	44
230	Mechanisms of Prostate Cancer Initiation and Progression. <i>Advances in Cancer Research</i> , 2010, 109, 1-50.	1.9	54
231	Genetic variation in RNASEL associated with prostate cancer risk and progression. <i>Carcinogenesis</i> , 2010, 31, 1597-1603.	1.3	54
232	Toll-like Receptor 3 Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance. <i>Cancer Research</i> , 2010, 70, 2595-2603.	0.4	95
233	The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. <i>Nature Reviews Urology</i> , 2010, 7, 392-402.	1.9	62
234	The Role of Vitamin D in Cancer Prevention and Treatment. <i>Endocrinology and Metabolism Clinics of North America</i> , 2010, 39, 401-418.	1.2	156
235	677 IDENTIFICATION OF EP4 AS A POTENTIAL TARGET FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER USING A NOVEL XENOGRAFT MODEL. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
236	TGF- β 2 signalling and immunity in prostate tumorigenesis. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 179-192.	1.5	20
237	Targeting Polyamines and Inflammation for Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2010, 188, 49-64.	1.8	61
238	Oxidative Stress in Benign Prostatic Hyperplasia and Prostate Cancer. <i>Urologia Internationalis</i> , 2010, 85, 328-333.	0.6	49
239	Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. <i>BMC Cancer</i> , 2010, 10, 315.	1.1	69
240	Molecular genetics of prostate cancer: new prospects for old challenges. <i>Genes and Development</i> , 2010, 24, 1967-2000.	2.7	811
241	Expression of E-Cadherin, Cox-2, P53 and BCL-2 in Prostate Carcinomas: Correlation with Tumor Differentiation and Metastatic Potential. <i>Biotechnology and Biotechnological Equipment</i> , 2010, 24, 2112-2116.	0.5	1
242	Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. <i>Human Pathology</i> , 2010, 41, 781-793.	1.1	243
243	Genetic Determinants of Cancer Susceptibility. , 2010, , 371-400.		2
244	Loss of Nkx3.1 Expression in Bacterial Prostatitis. <i>American Journal of Pathology</i> , 2010, 176, 2259-2268.	1.9	65
245	Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2010, 176, 393-401.	1.9	113
248	Nutrients and Risk of Prostate Cancer. <i>Nutrition and Cancer</i> , 2010, 62, 710-718.	0.9	20

#	ARTICLE	IF	CITATIONS
249	Comment on basal epithelial stem cells as efficient targets for prostate cancer initiation. <i>Stem Cell Research and Therapy</i> , 2010, 1, 16.	2.4	1
250	Comparison of men with acute versus chronic urinary retention: aetiology, clinical features and complications. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2011, 53, 590-594.	0.2	0
251	Persistent Inflammation Leads to Proliferative Neoplasia and Loss of Smooth Muscle Cells in a Prostate Tumor Model. <i>Neoplasia</i> , 2011, 13, 692-IN17.	2.3	37
252	Epigenetics and Chronic Diseases: An Overview. , 2011, , 1-20.		4
253	Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2011, 48, 155-170.	2.7	423
254	Prolactin regulation of the prostate gland: a female player in a male game. <i>Nature Reviews Urology</i> , 2011, 8, 597-607.	1.9	78
255	Prostate Cancer as a Model System for Genetic Diversity in Tumors. <i>Advances in Cancer Research</i> , 2011, 112, 183-216.	1.9	28
256	Cholesterol and benign prostate disease. <i>Differentiation</i> , 2011, 82, 244-252.	1.0	43
257	PPAR γ : A molecular link between systemic metabolic disease and benign prostate hyperplasia. <i>Differentiation</i> , 2011, 82, 220-236.	1.0	41
258	Role of interleukins, IGF and stem cells in BPH. <i>Differentiation</i> , 2011, 82, 237-243.	1.0	49
259	The anti-cancer and anti-inflammatory actions of 1,25(OH) $_2$ D $_3$. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 593-604.	2.2	84
260	The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. <i>Biochimie</i> , 2011, 93, 1369-1378.	1.3	81
261	Differential gene expression profiles of human leukemia cell lines exposed to benzene and its metabolites. <i>Environmental Toxicology and Pharmacology</i> , 2011, 32, 285-295.	2.0	18
262	Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D. <i>Annual Review of Pharmacology and Toxicology</i> , 2011, 51, 311-336.	4.2	408
263	Prevalence of <i>Propionibacterium acnes</i> in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. <i>International Journal of Medical Microbiology</i> , 2011, 301, 69-78.	1.5	126
264	Vitamin D metabolism and action in the prostate: Implications for health and disease. <i>Molecular and Cellular Endocrinology</i> , 2011, 347, 61-69.	1.6	46
265	Significance of focal proliferative atrophy lesions in prostate biopsy cores that test negative for prostate carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 690-697.	0.8	11
266	Nutrigenetics and Prostate Cancer: 2011 and Beyond. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2011, 4, 121-136.	1.8	10

#	ARTICLE	IF	CITATIONS
267	Improvement of Prostate Cancer Detection by Integrating the PSA Test With miRNA Expression Profiling. <i>Cancer Investigation</i> , 2011, 29, 318-324.	0.6	37
268	Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer. <i>Journal of Urology</i> , 2011, 185, 2102-2107.	0.2	76
269	Frequent Gene Products and Molecular Pathways Altered in Prostate Cancer- and Metastasis-Initiating Cells and Their Progenies and Novel Promising Multitargeted Therapies. <i>Molecular Medicine</i> , 2011, 17, 949-964.	1.9	52
270	Protective effect of carboxymethyl-glucan (CM-G) against DNA damage in patients with advanced prostate cancer. <i>Genetics and Molecular Biology</i> , 2011, 34, 131-135.	0.6	15
272	Investigating prostate cancer tumour-stroma interactions - clinical and biological insights from an evolutionary game. <i>Nature Precedings</i> , 2011, , .	0.1	1
273	Cyclooxygenase-2 Overexpression in Chronic Inflammation Associated with Benign Prostatic Hyperplasia: Is It Related to Apoptosis and Angiogenesis of Prostate Cancer?. <i>Korean Journal of Urology</i> , 2011, 52, 253.	1.2	36
274	Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e26595.	1.1	8
275	Dietary trans fatty acids and cancer risk. <i>European Journal of Cancer Prevention</i> , 2011, 20, 530-538.	0.6	46
276	Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 1867-1880.	0.9	10
277	ERG oncogene modulates prostaglandin signaling in prostate cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 11, 410-417.	1.5	30
278	Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer. <i>Oncology Reports</i> , 2011, 25, 1511-6.	1.2	8
279	NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. <i>Oncogene</i> , 2011, 30, 907-921.	2.6	211
280	IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. <i>Oncogene</i> , 2011, 30, 2345-2355.	2.6	136
281	Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1. <i>Oncogene</i> , 2011, 30, 3821-3832.	2.6	26
282	Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. <i>Oncogene</i> , 2011, 30, 4231-4242.	2.6	221
283	The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. <i>European Urology</i> , 2011, 60, 106-117.	0.9	351
284	Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. <i>Biochemical Pharmacology</i> , 2011, 82, 1073-1078.	2.0	213
285	Epidermal growth factor receptor transactivation is implicated in IL-6-induced proliferation and ERK1/2 activation in non-transformed prostate epithelial cells. <i>Cellular Signalling</i> , 2011, 23, 572-578.	1.7	16

#	ARTICLE	IF	CITATIONS
286	The Impact of Common Gene Variants on the Response of Biomarkers of Cardiovascular Disease (CVD) Risk to Increased Fish Oil Fatty Acids Intakes. <i>Annual Review of Nutrition</i> , 2011, 31, 203-234.	4.3	61
287	Associations of serum vitamin A and carotenoid levels with markers of prostate cancer detection among US men. <i>Cancer Causes and Control</i> , 2011, 22, 1483-1495.	0.8	19
288	Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 718-725.	1.0	7
289	Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. <i>Angiogenesis</i> , 2011, 14, 467-479.	3.7	73
290	H2O2 production within tumor microenvironment inversely correlated with infiltration of CD56dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1801-1810.	2.0	65
292	Testosterone Regulates Tight Junction Proteins and Influences Prostatic Autoimmune Responses. <i>Hormones and Cancer</i> , 2011, 2, 145-156.	4.9	45
293	The role of inflammation in breast cancer and prostate cancer. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 77-84.	0.1	0
294	Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. <i>BMC Cancer</i> , 2011, 11, 233.	1.1	44
295	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. <i>Molecular Cancer</i> , 2011, 10, 126.	7.9	170
296	Natriuretic Peptide Receptor A as a Novel Target for Prostate Cancer. <i>Molecular Cancer</i> , 2011, 10, 56.	7.9	29
297	Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. <i>Journal of Translational Medicine</i> , 2011, 9, 162.	1.8	59
298	A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. <i>Infectious Agents and Cancer</i> , 2011, 6, 25.	1.2	10
299	Promininâ€1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. <i>Prostate</i> , 2011, 71, 254-267.	1.2	44
300	Epigenetic silencing of <i>SOCS3</i> identifies a subset of prostate cancer with an aggressive behavior. <i>Prostate</i> , 2011, 71, 318-325.	1.2	71
301	Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4. <i>Prostate</i> , 2011, 71, 755-765.	1.2	70
302	An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. <i>Prostate</i> , 2011, 71, 1139-1150.	1.2	40
303	Insulinâ€like growth factorâ€2 (<i>IGF2</i>) loss of imprinting marks a field defect within human prostates containing cancer. <i>Prostate</i> , 2011, 71, 1621-1630.	1.2	55
304	Associations of aspirin, nonsteroidal antiâ€inflammatory drug and paracetamol use with PSAâ€detected prostate cancer: Findings from a large, populationâ€based, caseâ€control study (the ProtecT study). <i>International Journal of Cancer</i> , 2011, 128, 1442-1448.	2.3	41

#	ARTICLE	IF	CITATIONS
305	Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. <i>International Journal of Cancer</i> , 2011, 129, 424-432.	2.3	42
306	Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. <i>International Journal of Cancer</i> , 2011, 129, 1485-1492.	2.3	39
307	Infection, inflammation and prostate carcinogenesis. <i>Infection, Genetics and Evolution</i> , 2011, 11, 1195-1198.	1.0	31
308	Dietary Omega-3 Fatty Acids, Genetic Variation and Risk of Breast and Prostate Cancers. <i>World Review of Nutrition and Dietetics</i> , 2011, 102, 156-171.	0.1	6
309	Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4938-4943.	3.3	45
310	Macrophage-Dependent Cleavage of the Laminin Receptor $\alpha 1$ in Prostate Cancer. <i>Molecular Cancer Research</i> , 2011, 9, 1319-1328.	1.5	22
311	Pathways of chemotherapy resistance in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, R103-R123.	1.6	82
312	Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 923-933.	1.1	54
313	Modulators of Arginine Metabolism Do Not Impact on Peripheral T-Cell Tolerance and Disease Progression in a Model of Spontaneous Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1012-1023.	3.2	29
314	Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial. <i>American Journal of Epidemiology</i> , 2011, 173, 1419-1428.	1.6	57
315	Peroxiredoxin 1 Controls Prostate Cancer Growth through Toll-Like Receptor 4-Dependent Regulation of Tumor Vasculature. <i>Cancer Research</i> , 2011, 71, 1637-1646.	0.4	98
316	Prostate Cancer Immunotherapy: Figure 1.. <i>Clinical Cancer Research</i> , 2011, 17, 5233-5238.	3.2	57
317	XMRV, prostate cancer and chronic fatigue syndrome. <i>British Medical Bulletin</i> , 2011, 98, 61-74.	2.7	10
318	Molecular Determinants of the Response of Tumor Cells to Boswellic Acids. <i>Pharmaceuticals</i> , 2011, 4, 1171-1182.	1.7	12
319	Origins of Injection-Site Sarcomas in Cats: The Possible Role of Chronic Inflammation—A Review. <i>ISRN Veterinary Science</i> , 2011, 2011, 1-16.	1.1	27
320	Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?. <i>Clinical Cancer Research</i> , 2011, 17, 3858-3864.	3.2	92
321	Does an Inflammatory Pattern at Primary Biopsy Suggest a Lower Risk for Prostate Cancer at Repeated Saturation Prostate Biopsy. <i>Urologia Internationalis</i> , 2011, 87, 171-174.	0.6	15
322	Dietary zinc and prostate cancer survival in a Swedish cohort. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 586-593.	2.2	57

#	ARTICLE	IF	CITATIONS
323	Serum Phospholipid Fatty Acids and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. <i>American Journal of Epidemiology</i> , 2011, 173, 1429-1439.	1.6	127
324	Effect of experimentally induced diabetes on adult albino rats's ventral prostate gland and role of selenium. <i>Egyptian Journal of Histology</i> , 2011, 34, 311-322.	0.0	4
325	A Large Cohort Study of Long-term Acetaminophen Use and Prostate Cancer Incidence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1322-1328.	1.1	17
326	Circulating steroid hormones in prostate carcinogenesis. Part 2: Estrogens. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 6, 175-83.	0.3	0
327	Vascular Pericyte Density and Angiogenesis Associated with Adenocarcinoma of the Prostate. <i>Pathobiology</i> , 2011, 78, 24-34.	1.9	15
328	NF- κ B Activation Stimulates Transcription and Replication of Retrovirus XMRV in Human B-Lineage and Prostate Carcinoma Cells. <i>Journal of Virology</i> , 2011, 85, 3179-3186.	1.5	12
329	Genotyping of Sex Hormone-Related Pathways in Benign and Malignant Human Prostate Tissues: Data of a Preliminary Study. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 369-374.	1.0	14
331	Meat Consumption, Cooking Practices, Meat Mutagens, and Risk of Prostate Cancer. <i>Nutrition and Cancer</i> , 2011, 63, 525-537.	0.9	86
332	Risk of Prostate Cancer after Trans Urethral Resection of BPH: A Cohort and Nested Case-Control Study. <i>Cancers</i> , 2011, 3, 4127-4138.	1.7	6
333	Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. <i>Carcinogenesis</i> , 2011, 32, 1107-1121.	1.3	102
334	Vitamin D and Prostate Cancer. , 2011, , 1675-1709.		3
335	Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer. <i>Prostate Cancer</i> , 2011, 2011, 1-7.	0.4	33
336	The reactive stroma microenvironment and prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2012, 19, R187-R204.	1.6	251
337	Fine-Mapping of <i>IL16</i> Gene and Prostate Cancer Risk in African Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2059-2068.	1.1	19
338	Pro-Inflammatory S100A8 and S100A9 Proteins: Self-Assembly into Multifunctional Native and Amyloid Complexes. <i>International Journal of Molecular Sciences</i> , 2012, 13, 2893-2917.	1.8	164
339	Trichomonosis, a Common Curable STI, and Prostate Carcinogenesis—A Proposed Molecular Mechanism. <i>PLoS Pathogens</i> , 2012, 8, e1002801.	2.1	95
340	Immune Response to Sipuleucel-T in Prostate Cancer. <i>Cancers</i> , 2012, 4, 420-441.	1.7	12
341	Role of SOCS3 Evaluated by Immunohistochemical Analysis in a Cohort of Patients Affected by Prostate Cancer: Preliminary Results. <i>Urologia</i> , 2012, 79, 4-8.	0.3	10

#	ARTICLE	IF	CITATIONS
342	Variation in <i>IL10</i> and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1774-1782.	1.1	49
343	Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. <i>Carcinogenesis</i> , 2012, 33, 2507-2519.	1.3	149
344	Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 576-581.	1.1	43
345	Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression. <i>Clinical Cancer Research</i> , 2012, 18, 4291-4302.	3.2	61
346	HIV infection, aging, and immune function. <i>Current Opinion in Oncology</i> , 2012, 24, 506-516.	1.1	105
347	Identification of Differentially Expressed Proteins in Direct Expressed Prostatic Secretions of Men with Organ-confined Versus Extracapsular Prostate Cancer. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1870-1884.	2.5	71
348	Dietary Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5- <i>b</i>]Pyridine-Induced Prostate Carcinogenesis in CYP1A-Humanized Mice. <i>Cancer Prevention Research</i> , 2012, 5, 963-972.	0.7	33
349	Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia. <i>Journal of Virology</i> , 2012, 86, 8461-8471.	1.5	15
350	Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. <i>Modern Pathology</i> , 2012, 25, 1023-1032.	2.9	57
351	Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. <i>Journal of Endocrinology</i> , 2012, 212, 71-84.	1.2	165
352	Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game. <i>British Journal of Cancer</i> , 2012, 106, 174-181.	2.9	94
353	Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. <i>Journal of Endocrinology</i> , 2012, 214, 31-43.	1.2	119
354	Polyubiquitination of Transforming Growth Factor β^2 (TGF β^2)-associated Kinase 1 Mediates Nuclear Factor- κ B Activation in Response to Different Inflammatory Stimuli. <i>Journal of Biological Chemistry</i> , 2012, 287, 123-133.	1.6	54
355	Proline-mediated Proteasomal Degradation of the Prostate-specific Tumor Suppressor NKX3.1. <i>Journal of Biological Chemistry</i> , 2012, 287, 36331-36340.	1.6	9
356	Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from a multiethnic case-control study. <i>Carcinogenesis</i> , 2012, 33, 2108-2118.	1.3	64
357	Positive Selection on the Gene RNASEL: Correlation between Patterns of Evolution and Function. <i>Molecular Biology and Evolution</i> , 2012, 29, 3161-3168.	3.5	12
358	MIF in the Pathogenesis of Urological Cancer. , 2012, , 279-294.		0
359	Overcoming docetaxel resistance in prostate cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 329-340.	1.4	114

#	ARTICLE	IF	CITATIONS
361	Tissue Biomarkers for Prostate Cancer Radiation Therapy. <i>Current Molecular Medicine</i> , 2012, 12, 772-787.	0.6	19
362	Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: A biopsy study in chronic prostatitis patients. <i>International Journal of Oncology</i> , 2012, 41, 1950-1958.	1.4	31
363	Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer. <i>Oncology Letters</i> , 2012, 3, 1166-1170.	0.8	13
364	Lifestyle and dietary factors in the prevention of lethal prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 365-374.	0.8	100
365	Oral exposure to methylmercury modifies the prostatic microenvironment in adult rats. <i>International Journal of Experimental Pathology</i> , 2012, 93, 354-360.	0.6	17
366	Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. <i>Cancer Causes and Control</i> , 2012, 23, 1511-1518.	0.8	15
367	Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductase. <i>FEBS Open Bio</i> , 2012, 2, 119-128.	1.0	43
368	Acoustic Radiation Force Impulse Imaging of Human Prostates: Initial In Vivo Demonstration. <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 50-61.	0.7	59
369	The Role of Vitamin D in Cancer Prevention and Treatment. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 161-178.	0.8	51
370	Interleukin-17 Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse Models. <i>Cancer Research</i> , 2012, 72, 2589-2599.	0.4	84
371	Association of Polymorphisms in MCP-1, CCR2, and CCR5 Genes with the Risk and Clinicopathological Characteristics of Prostate Cancer. <i>DNA and Cell Biology</i> , 2012, 31, 1418-1424.	0.9	29
373	Biology of Castration-Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 435-452.	0.8	28
374	Low serum neutrophil count predicts a positive prostate biopsy. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 386-390.	2.0	35
375	PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21. <i>American Journal of Pathology</i> , 2012, 180, 2097-2107.	1.9	72
376	Ciprofloxacin as a prophylactic agent against prostate cancer: A two-hit hypothesis. <i>Medical Hypotheses</i> , 2012, 78, 235-238.	0.8	6
377	Breaking through a roadblock in prostate cancer research: An update on human model systems. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 131, 122-131.	1.2	37
378	Association between C3orf21, TP63 polymorphisms and environment and NSCLC in never-smoking Chinese population. <i>Gene</i> , 2012, 497, 93-97.	1.0	16
379	Histological chronic prostatitis and high-grade prostate intraepithelial neoplasia do not influence urinary prostate cancer gene 3 score. <i>BJU International</i> , 2012, 110, E778-82.	1.3	9

#	ARTICLE	IF	CITATIONS
380	Innate Immune Signaling and Negative Regulators in Cancer. , 2012, , 61-88.		1
381	Global Levels of H3K27me3 Track with Differentiation in Vivo and Are Deregulated by MYC in Prostate Cancer. American Journal of Pathology, 2012, 181, 560-569.	1.9	54
382	Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer and Prostatic Diseases, 2012, 15, 28-35.	2.0	37
384	Evidence-based Anticancer Materia Medica for Prostate Cancer. Evidence-based Anticancer Complementary and Alternative Medicine, 2012, , 103-127.	0.1	0
385	Prostatic Masses in Geldings: Two Cases. Journal of Equine Veterinary Science, 2012, 32, 628-633.	0.4	4
386	Human prostate cancer cells induce inflammatory cytokine secretion by peripheral blood mononuclear cells. Biomedicine and Pharmacotherapy, 2012, 66, 330-333.	2.5	15
387	Profile of NF- κ Bp(65/NF- κ Bp50) among prostate specific antigen sera levels in prostatic pathologies. Pathologie Et Biologie, 2012, 60, 301-305.	2.2	7
388	Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: The best and the worst. Molecular Oncology, 2012, 6, 473-483.	2.1	9
389	Bioactive Sterols from Marine Resources and Their Potential Benefits for Human Health. Advances in Food and Nutrition Research, 2012, 65, 261-268.	1.5	10
390	Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nature Genetics, 2012, 44, 1231-1235.	9.4	160
391	Enhancing Cancer Immunotherapy by Intracellular Delivery of Cell-Penetrating Peptides and Stimulation of Pattern-Recognition Receptor Signaling. Advances in Immunology, 2012, 114, 151-176.	1.1	30
392	Oxidative Stress in Benign Prostate Hyperplasia. , 2012, , 591-615.		1
393	Unveiling the Association of STAT3 and HO-1 in Prostate Cancer: Role beyond Heme Degradation. Neoplasia, 2012, 14, 1043-1056.	2.3	39
394	Association between SDF1-3 Δ 2A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases. Molecular Biology Reports, 2012, 39, 11073-11079.	1.0	21
395	Oxidative Stress in Cancer Biology and Therapy. , 2012, , .		5
397	Pathobiological Implications of the Expression of EGFR, pAkt, NF- κ B and MIC-1 in Prostate Cancer Stem Cells and Their Progenies. PLoS ONE, 2012, 7, e31919.	1.1	46
398	Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial. PLoS ONE, 2012, 7, e47079.	1.1	45
399	Peroxiredoxin 1 Stimulates Endothelial Cell Expression of VEGF via TLR4 Dependent Activation of HIF-1 α . PLoS ONE, 2012, 7, e50394.	1.1	68

#	ARTICLE	IF	CITATIONS
400	Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. <i>Clinical Epidemiology</i> , 2012, 4, 1.	1.5	184
401	The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. <i>Research and Reports in Urology</i> , 2012, 5, 1.	0.6	38
402	Testosterone and the prostate. , 0, , 268-291.		3
403	Challenges to Prostate Cancer Immunotherapy. , 0, , .		1
404	Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. <i>Prostate</i> , 2012, 72, 209-216.	1.2	22
405	Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. <i>Prostate</i> , 2012, 72, 487-498.	1.2	13
406	The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo. <i>Prostate</i> , 2012, 72, 677-689.	1.2	18
407	IgG gene expression and its possible significance in prostate cancers. <i>Prostate</i> , 2012, 72, 690-701.	1.2	35
408	Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization. <i>Prostate</i> , 2012, 72, 1159-1170.	1.2	16
409	A <i>Hoxb13</i> -driven reverse tetracycline transactivator system for conditional gene expression in the prostate. <i>Prostate</i> , 2012, 72, 1045-1051.	1.2	9
410	Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. <i>Prostate</i> , 2012, 72, 1628-1637.	1.2	27
411	A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. <i>Prostate</i> , 2012, 72, 1779-1788.	1.2	56
412	Interleukin-6 promoter variants, prostate cancer risk, and survival. <i>Prostate</i> , 2012, 72, 1701-1707.	1.2	22
413	S100A8/A9 Amyloidosis in the Ageing Prostate: Relating Ex Vivo and In Vitro Studies. <i>Methods in Molecular Biology</i> , 2012, 849, 387-401.	0.4	8
414	The Role of Vitamin E in Prostate Cancer. , 2012, , 333-354.		0
415	Oxidative Stress in Prostate Cancer. , 2012, , 301-331.		2
416	Circumcision and the risk of prostate cancer. <i>Cancer</i> , 2012, 118, 4437-4443.	2.0	45
417	Serum Levels of Secreted Group IIA Phospholipase A2 in Benign Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation or Neoplasia?. <i>Inflammation</i> , 2012, 35, 1113-1118.	1.7	21

#	ARTICLE	IF	CITATIONS
418	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 453-468.	2.0	22
419	Sequence variants of toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. <i>World Journal of Urology</i> , 2012, 30, 225-232.	1.2	25
420	Androgen receptor footprint on the way to prostate cancer progression. <i>World Journal of Urology</i> , 2012, 30, 279-285.	1.2	21
421	Prostate cancer and inflammation: the evidence. <i>Histopathology</i> , 2012, 60, 199-215.	1.6	491
422	The Correlation Between Metabolic Syndrome and Prostatic Diseases. <i>European Urology</i> , 2012, 61, 560-570.	0.9	297
423	Antioxidants for prostate cancer chemoprevention: Challenges and opportunities. <i>Biochemical Pharmacology</i> , 2012, 83, 1319-1330.	2.0	54
424	Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. <i>Annals of the New York Academy of Sciences</i> , 2012, 1253, 159-169.	1.8	36
425	Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate. <i>BJU International</i> , 2012, 109, 1194-1197.	1.3	7
426	Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 439-448.	0.9	25
427	Bromelain inhibits nuclear factor kappa-B translocation, driving human epidermoid carcinoma A431 and melanoma A375 cells through G ₂ /M arrest to apoptosis. <i>Molecular Carcinogenesis</i> , 2012, 51, 231-243.	1.3	65
428	Cyclooxygenase-2 expression in central giant cell lesion of the jaws: an immunohistochemical study. <i>Journal of Molecular Histology</i> , 2012, 43, 59-62.	1.0	3
429	RNASL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis. <i>Molecular Biology Reports</i> , 2012, 39, 2347-2353.	1.0	13
430	Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. <i>Genome Medicine</i> , 2013, 5, 29.	3.6	96
431	Expression of SOCSs in human prostate cancer and their association in prognosis. <i>Molecular and Cellular Biochemistry</i> , 2013, 381, 51-59.	1.4	40
433	The Role of Inflammation in the Progression of Benign Prostatic Hyperplasia. <i>Current Bladder Dysfunction Reports</i> , 2013, 8, 142-149.	0.2	13
434	Evidence supporting the association of polyomavirus BK genome with prostate cancer. <i>Medical Microbiology and Immunology</i> , 2013, 202, 425-430.	2.6	20
435	Folate and B12 in Prostate Cancer. <i>Advances in Clinical Chemistry</i> , 2013, 60, 1-63.	1.8	25
436	Prostate Cancer Takes Nerve. <i>Science</i> , 2013, 341, 134-135.	6.0	15

#	ARTICLE	IF	CITATIONS
437	A comparative study of tissue i%6 and i%3 polyunsaturated fatty acids (PUFA) in benign and malignant pathologic stage pT2a radical prostatectomy specimens. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 318-324.	0.8	17
438	Upregulation of miRâ€153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. <i>Prostate</i> , 2013, 73, 596-604.	1.2	107
439	TGFÎ²1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 206-213.	1.2	13
440	The Link Between Benign Prostatic Hyperplasia and Inflammation. <i>European Urology Supplements</i> , 2013, 12, 103-109.	0.1	19
441	Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-Î± signaling pathways in prostate cancer. <i>Cytokine</i> , 2013, 64, 555-563.	1.4	57
442	Immunity, inflammation and cancer: a leading role for adenosine. <i>Nature Reviews Cancer</i> , 2013, 13, 842-857.	12.8	612
443	Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1613-1626.	1.9	25
444	Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent. <i>Genes and Immunity</i> , 2013, 14, 347-355.	2.2	19
445	Xenograft, Transgenic, and Knockout Models of Prostate Cancer. , 2013, , 973-995.		11
446	MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. <i>Cardiovascular Research</i> , 2013, 100, 7-18.	1.8	277
447	Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 423-430.	0.9	36
448	Prostate Cancer: Shifting from Morphology to Biology. , 2013, , .		1
449	Anti-inflammatory and antioxidant activity of thymoquinone in a rat model of acute bacterial prostatitis. <i>Human and Experimental Toxicology</i> , 2013, 32, 354-361.	1.1	30
450	Positive correlation between PEDF expression levels and macrophage density in the human prostate. <i>Prostate</i> , 2013, 73, 549-561.	1.2	25
451	Novel Oncogeneâ€Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures. <i>Cancer Research</i> , 2013, 73, 978-989.	0.4	25
452	Inflammation and prostate carcinogenesis. <i>International Journal of Urology</i> , 2013, 20, 150-160.	0.5	86
453	Common genetic variants associated with disease from genomeâ€wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. <i>BJU International</i> , 2013, 111, 1148-1155.	1.3	9
454	Melatonin MT₁ receptorâ€induced transcriptional upâ€regulation of p27^{Kip1} in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NFâ€KB): potential implications on prostate cancer chemoprevention and therapy. <i>Journal of Pineal Research</i> , 2013, 54, 69-79.	3.4	54

#	ARTICLE	IF	CITATIONS
455	Can mycoplasma contribute to formation of prostate cancer?. International Urology and Nephrology, 2013, 45, 33-38.	0.6	16
456	Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men. Cancer Genetics, 2013, 206, 266-278.	0.2	22
457	Potential of Inflammatory CXCL8 Signalling Sustains Cell Survival in PTEN-deficient Prostate Carcinoma. European Urology, 2013, 64, 177-188.	0.9	67
458	Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer Patients. Clinical Genitourinary Cancer, 2013, 11, 211-220.	0.9	17
459	A Double-Blind, Randomized, Neoadjuvant Study of the Tissue Effects of POMx Pills in Men with Prostate Cancer Before Radical Prostatectomy. Cancer Prevention Research, 2013, 6, 1120-1127.	0.7	61
460	Oncogenic Herpesvirus HHV-8 Promotes Androgen-Independent Prostate Cancer Growth. Cancer Research, 2013, 73, 5695-5708.	0.4	14
461	Chronic Inflammatory Infiltrate and Benign Prostatic Hyperplasia: What Do We Know?. European Urology Supplements, 2013, 12, 99-102.	0.1	3
462	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. European Journal of Cancer, 2013, 49, 1273-1279.	1.3	101
463	Effect of Microbubble-enhanced Ultrasound on Prostate Permeability: A Potential Therapeutic Method for Prostate Disease. Urology, 2013, 81, 921.e1-921.e7.	0.5	13
464	Detectability and reproducibility of plasma levels of chemokines and soluble receptors. Results in Immunology, 2013, 3, 79-84.	2.2	21
465	Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 951-965.	0.8	33
466	Predictors of mortality in patients with stress-induced cardiomyopathy developed during critical care. Journal of Critical Care, 2013, 28, 618-624.	1.0	7
467	Prostate cancer: is it time to expand the research focus to early-life exposures?. Nature Reviews Cancer, 2013, 13, 208-518.	12.8	76
468	Interplay of reactive oxygen species, intracellular Ca ²⁺ and mitochondrial homeostasis in the apoptosis of prostate cancer cells by deoxy podophyllotoxin. Journal of Cellular Biochemistry, 2013, 114, 1124-1134.	1.2	42
469	Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer. Oncogene, 2013, 32, 1601-1608.	2.6	33
470	The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (<sc>BPH</sc>). BJU International, 2013, 112, 432-441.	1.3	211
471	Consumption of deep-fried foods and risk of prostate cancer. Prostate, 2013, 73, 960-969.	1.2	57
472	An introduction to acinar pressures in BPH and prostate cancer. Nature Reviews Urology, 2013, 10, 358-366.	1.9	7

#	ARTICLE	IF	CITATIONS
473	PTEN in Prostate Cancer. , 2013, , 87-137.		2
474	A new role for microRNAs, as ligands of Toll-like receptors. RNA Biology, 2013, 10, 169-174.	1.5	125
475	CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer. Human Immunology, 2013, 74, 1003-1008.	1.2	25
476	Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis. Cellular and Molecular Biology Letters, 2013, 18, 355-67.	2.7	23
477	A New Proposed Rodent Model of Chemically Induced Prostate Carcinogenesis: Distinct Time-Course Prostate Cancer Progression in the Dorsolateral and Ventral Lobes. Prostate, 2013, 73, 1202-1213.	1.2	26
478	A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of <i>Propionibacterium acnes</i> . Prostate, 2013, 73, 1007-1015.	1.2	107
479	Inflammation and Cancer of the Prostate. , 2013, , 115-122.		0
480	Epigenetic Changes in Prostate Cancer. , 2013, , 169-179.		0
481	Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochemical Pharmacology, 2013, 85, 1398-1404.	2.0	174
482	Anticancer Property of Bromelain With Therapeutic Potential in Malignant Peritoneal Mesothelioma. Cancer Investigation, 2013, 31, 241-250.	0.6	43
483	Serum amyloid A, phospholipase A2-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. Inflammation Research, 2013, 62, 1063-1072.	1.6	17
484	Multilocus sequence typing (MLST) analysis of <i>Propionibacterium acnes</i> isolates from radical prostatectomy specimens. Prostate, 2013, 73, 770-777.	1.2	51
485	Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer, 2013, 49, 938-945.	1.3	65
487	Expression of proton-coupled oligopeptide transporter (POTs) in prostate of mice and patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Prostate, 2013, 73, 287-295.	1.2	10
488	Effect of ageing on albino rat female prostate (paraurethral glands). Egyptian Journal of Histology, 2013, 36, 735-745.	0.0	0
489	ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes and Development, 2013, 27, 683-698.	2.7	163
490	HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer, 2013, 2013, 1-8.	0.4	42
491	Effect of melatonin on contractile activity in intraurethrally instilled E. coli-induced acute prostatitis rat model. Turkish Journal of Medical Sciences, 2013, 43, 905-912.	0.4	0

#	ARTICLE	IF	CITATIONS
492	Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-9.	0.5	4
493	Clinical Applications of Recent Molecular Advances in Urologic Malignancies. <i>Advances in Anatomic Pathology</i> , 2013, 20, 175-203.	2.4	26
494	Preneoplasia in the prostate gland with emphasis on high grade prostatic intraepithelial neoplasia. <i>Pathology</i> , 2013, 45, 251-263.	0.3	17
495	ETS Transcription Factor ESE1/ELF3 Orchestrates a Positive Feedback Loop That Constitutively Activates NF- κ B and Drives Prostate Cancer Progression. <i>Cancer Research</i> , 2013, 73, 4533-4547.	0.4	72
496	Loss of estrogen-related receptor β promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17975-17980.	3.3	60
497	Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating Androgen Receptor-Mediated CCL4 \rightarrow STAT3 Signaling. <i>Cancer Research</i> , 2013, 73, 5633-5646.	0.4	125
498	The Impact of Obesity on Benign and Malignant Urologic Conditions. <i>Postgraduate Medicine</i> , 2013, 125, 53-69.	0.9	39
499	AIM2, an IFN-Inducible Cytosolic DNA Sensor, in the Development of Benign Prostate Hyperplasia and Prostate Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 1193-1202.	1.5	97
500	Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. <i>Carcinogenesis</i> , 2013, 34, 113-120.	1.3	28
501	Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. <i>Endocrine-Related Cancer</i> , 2013, 20, R269-R290.	1.6	57
502	Interleukin-6 and Oncostatin-M Synergize with the PI3K/AKT Pathway to Promote Aggressive Prostate Malignancy in Mouse and Human Tissues. <i>Molecular Cancer Research</i> , 2013, 11, 1159-1165.	1.5	44
503	Antioxidative and Anti-inflammatory Effect of Thymoquinone in an Acute <i>Pseudomonas</i> Prostatitis Rat Model. <i>Urologia Internationalis</i> , 2013, 91, 474-481.	0.6	29
504	Correlation between benign prostatic hyperplasia and inflammation. <i>Current Opinion in Urology</i> , 2013, 23, 5-10.	0.9	122
505	Blood Level Omega-3 Fatty Acids as Risk Determinant Molecular Biomarker for Prostate Cancer. <i>Prostate Cancer</i> , 2013, 2013, 1-15.	0.4	12
506	Antineoplastic effects of 1,25(OH) $_2$ D $_3$ and its analogs in breast, prostate and colorectal cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R31-R47.	1.6	99
507	Molecular Detection of Prostate Cancer by Methylation-Specific Polymerase Chain Reaction from Urine Specimens. <i>Journal of Medical Biochemistry</i> , 2013, 32, 233-237.	0.7	1
508	Metastasis of a Prostatic Carcinoma along an Omental Graft in a Dog. <i>Case Reports in Veterinary Medicine</i> , 2013, 2013, 1-5.	0.2	2
509	The role of C-reactive protein in prostate cancer. <i>Cancer</i> , 2013, 119, 3262-3264.	2.0	6

#	ARTICLE	IF	CITATIONS
510	<i>MSMB</i> gene variant alters the association between prostate cancer and number of sexual partners. <i>Prostate</i> , 2013, 73, 1803-1809.	1.2	9
511	<i>TLR7</i> Expression is Decreased During Tumour Progression in Transgenic Adenocarcinoma of Mouse Prostate Mice and Its Activation Inhibits Growth of Prostate Cancer Cells. <i>American Journal of Reproductive Immunology</i> , 2013, 70, 317-326.	1.2	10
512	Prediagnostic circulating markers of inflammation and risk of prostate cancer. <i>International Journal of Cancer</i> , 2013, 133, 2961-2967.	2.3	40
513	Active surveillance: Does serial prostate biopsy increase histological inflammation?. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 165-169.	2.0	16
514	Proteolysis of Complement Factors <i>iC3b</i> and <i>C5</i> by the Serine Protease Prostate-Specific Antigen in Prostatic Fluid and Seminal Plasma. <i>Journal of Immunology</i> , 2013, 190, 2567-2574.	0.4	22
515	Does the microenvironment influence the cell types of origin for prostate cancer?. <i>Genes and Development</i> , 2013, 27, 1539-1544.	2.7	32
516	Indole-3-Carbinol and 3,3'-Diindolylmethane Modulate Androgen's Effect on C-C Chemokine Ligand 2 and Monocyte Attraction to Prostate Cancer Cells. <i>Cancer Prevention Research</i> , 2013, 6, 519-529.	0.7	14
517	Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (<i>PSA</i>) concentration in the Finnish prostate cancer screening trial. <i>BJU International</i> , 2013, 112, 735-741.	1.3	56
518	Marine-Derived Nutraceuticals: Trends and Prospects		
519	Cancer Chemoprevention by Traditional Chinese Herbal Medicine and Dietary Phytochemicals: Targeting Nrf2-Mediated Oxidative Stress/Anti-Inflammatory Responses, Epigenetics, and Cancer Stem Cells. <i>Journal of Traditional and Complementary Medicine</i> , 2013, 3, 69-79.	1.5	35
520	In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod. <i>International Journal of Oncology</i> , 2013, 42, 2087-2093.	1.4	34
521	Age-related alterations in T lymphocytes modulate key pathways in prostate tumorigenesis. <i>Prostate</i> , 2013, 73, 855-864.	1.2	10
522	Increased risk of prostate cancer following sexually transmitted infection in an Asian population. <i>Epidemiology and Infection</i> , 2013, 141, 2663-2670.	1.0	12
523	Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: A meta-analysis. <i>Biomedical Reports</i> , 2013, 1, 433-439.	0.9	14
524	The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A Meta-analysis. <i>Canadian Urological Association Journal</i> , 2013, 7, 333.	0.3	29
525	The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e58504.	1.1	38
526	ARLTS1 and Prostate Cancer Risk - Analysis of Expression and Regulation. <i>PLoS ONE</i> , 2013, 8, e72040.	1.1	12
527	Heme Oxygenase-1 (HO-1) Expression in Prostate Cancer Cells Modulates the Oxidative Response in Bone Cells. <i>PLoS ONE</i> , 2013, 8, e80315.	1.1	15

#	ARTICLE	IF	CITATIONS
528	Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis. <i>Frontiers in Genetics</i> , 2013, 4, 80.	1.1	74
529	Prostate Cancer, Inflammation and Antioxidants. , 0, , .		3
530	Is There an Infectious Agent Behind Prostate Cancer?. , 0, , .		0
531	Inflammatory Microenvironment in Prostate Carcinogenesis. , 2013, , .		1
532	A Glance at the Complexity of Nutrition and the Prostate: Considering Molecular Targets to Unravel the Most Recent Controversy Between Omega-3 Fatty Acids and Their Impact on Prostate Cancer Risk. , 0, , .		0
533	Integrins in Prostate Cancer Invasion and Metastasis. , 2013, , .		3
534	The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment. <i>Nutrients</i> , 2014, 6, 4491-4519.	1.7	18
535	Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e110569.	1.1	24
536	Intracellular Propionibacterium acnes Infection in Glandular Epithelium and Stromal Macrophages of the Prostate with or without Cancer. <i>PLoS ONE</i> , 2014, 9, e90324.	1.1	45
537	Distinct Phenotypes of Human Prostate Cancer Cells Associate with Different Adaptation to Hypoxia and Pro-Inflammatory Gene Expression. <i>PLoS ONE</i> , 2014, 9, e96250.	1.1	54
538	Is Bladder Tumor Location Associated with Prostate Cancer Detection after Intravesical Bacillus Calmette-Guérin Instillation?. <i>PLoS ONE</i> , 2014, 9, e103791.	1.1	4
539	Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	29
540	IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. <i>Research and Reports in Urology</i> , 2014, 6, 27.	0.6	26
541	Incidental prostate 18F-FDG uptake without calcification indicates the possibility of prostate cancer. <i>Oncology Reports</i> , 2014, 31, 1517-1522.	1.2	27
542	Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 847-856.	1.1	195
543	Mechanisms and pathways of innate immune activation and regulation in health and cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3270-3285.	1.4	246
544	Oncogenic fusion proteins expressed in immature hematopoietic cells fail to recapitulate the transcriptional changes observed in human AML. <i>Oncogenesis</i> , 2014, 3, e106-e106.	2.1	6
545	PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF- κ B. <i>Oncogenesis</i> , 2014, 3, e114-e114.	2.1	47

#	ARTICLE	IF	CITATIONS
546	The Diet as a Cause of Human Prostate Cancer. <i>Cancer Treatment and Research</i> , 2014, 159, 51-68.	0.2	38
547	L-Selenomethionine Does Not Protect Against Testosterone Plus 17 β -Estradiol-Induced Oxidative Stress and Preneoplastic Lesions in the Prostate of NBL Rats. <i>Nutrition and Cancer</i> , 2014, 66, 825-834.	0.9	8
548	Oxidative Stress and Prostate Cancer. , 2014, , 15-22.		3
549	Toad Glandular Secretions and Skin Extractions as Anti-Inflammatory and Anticancer Agents. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-9.	0.5	47
550	The Effect of LHRH Antagonist Cetrorelix in Crossover Conditioned Media from Epithelial (BPH-1) and Stromal (WPMY-1) Prostate Cells. <i>Hormone and Metabolic Research</i> , 2014, 46, 21-26.	0.7	10
551	A pro-tumorigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. <i>Journal of Pathology</i> , 2014, 234, 86-98.	2.1	47
553	Expression of phosphorylated-mTOR during the development of prostate cancer. <i>Prostate</i> , 2014, 74, 1231-1239.	1.2	21
554	Intriguing data on inflammation and prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 369-370.	1.9	24
555	Sexual partners, sexually transmitted infections, and prostate cancer risk. <i>Cancer Epidemiology</i> , 2014, 38, 700-707.	0.8	31
556	Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. <i>British Journal of Cancer</i> , 2014, 111, 1421-1431.	2.9	26
557	The Prodrug Platin \rightarrow : Simultaneous Release of Cisplatin and Aspirin. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 1963-1967.	7.2	230
558	Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. <i>Prostate</i> , 2014, 74, 1452-1461.	1.2	95
559	Novel method to characterize immune cells from human prostate tissue. <i>Prostate</i> , 2014, 74, 1391-1399.	1.2	10
561	A Peripheral Circulating TH1 Cytokine Profile Is Inversely Associated with Prostate Cancer Risk in CLUE II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2561-2567.	1.1	18
562	MTA family of proteins in prostate cancer: biology, significance, and therapeutic opportunities. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 929-942.	2.7	25
563	Analysis of the Expression of Interleukins, Interferon γ , and Nuclear Factor- κ B in Prostate Cancer and their Relationship With Biochemical Recurrence. <i>Journal of Immunotherapy</i> , 2014, 37, 366-373.	1.2	16
564	Inflammation promotes prostate differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1666-1667.	3.3	16
565	Toll-Like Receptors and Prostate Cancer. <i>Frontiers in Immunology</i> , 2014, 5, 352.	2.2	86

#	ARTICLE	IF	CITATIONS
566	The Role of Inflammation in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014, 816, 153-181.	0.8	77
567	Zoledronic Acid Elicits Proinflammatory Cytokine Profile in Osteolytic Prostate Cancer Cells. <i>ISRN Pathology</i> , 2014, 2014, 1-8.	0.4	3
568	Senescent Remodeling of the Innate and Adaptive Immune System in the Elderly Men with Prostate Cancer. <i>Current Gerontology and Geriatrics Research</i> , 2014, 2014, 1-11.	1.6	18
569	Exposure of Prostate to Lipopolysaccharide and Hypoxia Potentiates Neoplastic Behavior and Risk for Prostate Carcinogenesis In Vivo. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-6.	0.9	3
570	<i>Psychology and Cancer</i> . , 2014, , 81-223.		1
571	The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation. <i>Cancer Cell International</i> , 2014, 14, 54.	1.8	16
572	Inflammation-mediated abrogation of androgen signaling: An in vitro model of prostate cell inflammation. <i>Molecular Carcinogenesis</i> , 2014, 53, 85-97.	1.3	43
573	Oroxilin a prevents inflammation-related tumor through down-regulation of inflammatory gene expression by inhibiting NF- κ B signaling. <i>Molecular Carcinogenesis</i> , 2014, 53, 145-158.	1.3	47
574	Significado clnico de la atrofia proliferativa inflamatoria en la biopsia prosttica. <i>Actas Urolgicas Espaolas</i> , 2014, 38, 122-126.	0.3	7
575	Takotsubo Syndrome (Stress Cardiomyopathy): An Intriguing Clinical Condition in Search of Its Identity. <i>American Journal of Medicine</i> , 2014, 127, 699-704.	0.6	66
576	Anti-inflammatory effect of Marchantin M contributes to sensitization of prostate cancer cells to docetaxel. <i>Cancer Letters</i> , 2014, 348, 126-134.	3.2	16
577	Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. <i>BMC Cancer</i> , 2014, 14, 106.	1.1	20
578	Coffee consumption and prostate cancer risk: an updated meta-analysis. <i>Cancer Causes and Control</i> , 2014, 25, 591-604.	0.8	40
579	Mechanism of pro-tumorigenic effect of BMP6: Neovascularization involving tumor-associated macrophages and IL-1 β . <i>Prostate</i> , 2014, 74, 121-133.	1.2	28
580	Statin Use and the Risk of Recurrence After Radical Prostatectomy in a Cohort of Men With Inherited and/or Early-onset Forms of Prostate Cancer. <i>Urology</i> , 2014, 83, 1356-1361.	0.5	13
581	<i>Molecular Testing in Cancer</i> . , 2014, , .		2
582	Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E592-600.	3.3	159
583	Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. <i>Carcinogenesis</i> , 2014, 35, 2074-2083.	1.3	73

#	ARTICLE	IF	CITATIONS
584	Clinical significance of proliferative inflammatory atrophy in prostate biopsy. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 122-126.	0.2	3
585	Procyanidin B2 3,3^{â€³}-di-O-gallate, a Biologically Active Constituent of Grape Seed Extract, Induces Apoptosis in Human Prostate Cancer Cells Via Targeting NF-Î²B, Stat3, and AP1 Transcription Factors. <i>Nutrition and Cancer</i> , 2014, 66, 736-746.	0.9	30
586	Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population. <i>Gene</i> , 2014, 533, 86-93.	1.0	22
587	Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. <i>Cancer Gene Therapy</i> , 2014, 21, 2-11.	2.2	15
588	Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. <i>Blood</i> , 2014, 123, 894-904.	0.6	133
589	<i>MSMB</i> variation and prostate cancer risk: Clues towards a possible fungal etiology. <i>Prostate</i> , 2014, 74, 569-578.	1.2	36
590	White blood cell count is positively associated with benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2014, 21, 308-312.	0.5	14
591	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. <i>Urology</i> , 2014, 84, 1073-1080.	0.5	2
592	Interleukin-Driven Insulin-Like Growth Factor Promotes Prostatic Inflammatory Hyperplasia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 605-615.	1.3	12
593	Signification dâ€™une hyperfixation prostatique du fluorodâ€™soxyglucose (18F) chez un patient sans antécédent de cancer de la prostate. <i>Cas cliniques, revue et méta-analyse de la littérature. Médecine Nucleaire</i> , 2014, 38, 266-274.	0.2	1
594	The Biological Significance of Zinc in Inflammation and Aging. , 2014, , 15-27.		11
595	Management of Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , .	0.0	2
596	Effect of a Low-Fat Fish Oil Diet on Proinflammatory Eicosanoids and Cell-Cycle Progression Score in Men Undergoing Radical Prostatectomy. <i>Cancer Prevention Research</i> , 2014, 7, 97-104.	0.7	36
597	Pentraxin 3: A Novel Biomarker for Predicting Progression from Prostatic Inflammation to Prostate Cancer. <i>Cancer Research</i> , 2014, 74, 4230-4238.	0.4	74
598	Future directions in the prevention of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 49-60.	12.5	42
599	Chemical glycosylation of cytochrome c improves physical and chemical protein stability. <i>BMC Biochemistry</i> , 2014, 15, 16.	4.4	23
600	Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer. <i>BMC Medical Genomics</i> , 2014, 7, 50.	0.7	16
601	Prevention and early detection of prostate cancer. <i>Lancet Oncology, The</i> , 2014, 15, e484-e492.	5.1	372

#	ARTICLE	IF	CITATIONS
602	Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. Journal of Ethnopharmacology, 2014, 157, 105-113.	2.0	42
603	Genetic variation across C-reactive protein and risk of prostate cancer. Prostate, 2014, 74, 1034-1042.	1.2	14
604	Metabolic Reprogramming of Stromal Fibroblasts through p62-mTORC1 Signaling Promotes Inflammation and Tumorigenesis. Cancer Cell, 2014, 26, 121-135.	7.7	258
605	Effects of maternal diabetes on male offspring: high cell proliferation and increased activity of MMP-2 in the ventral prostate. Cell and Tissue Research, 2014, 358, 257-269.	1.5	7
606	An EP4 Antagonist ONO-AE3-208 Suppresses Cell Invasion, Migration, and Metastasis of Prostate Cancer. Cell Biochemistry and Biophysics, 2014, 70, 521-527.	0.9	27
607	miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells. Medical Oncology, 2014, 31, 910.	1.2	44
608	Association of rhinosinusitis with nasopharyngeal carcinoma: A population-based study. Laryngoscope, 2014, 124, 1515-1520.	1.1	29
609	Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?. Biomedicine and Pharmacotherapy, 2014, 68, 21-24.	2.5	14
610	Relationship of Chronic Histologic Prostatic Inflammation in Biopsy Specimens With Serum Isoform [-2]proPSA (p2PSA), %p2PSA, and Prostate Health Index in Men With a Total Prostate-specific Antigen of 4-10 ng/mL and Normal Digital Rectal Examination. Urology, 2014, 83, 606-612.	0.5	34
611	The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clinical Biochemistry, 2014, 47, 909-915.	0.8	31
612	Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease-The 2001-2008 National Health and Nutrition examination survey. Prostate, 2014, 74, 561-567.	1.2	48
613	Tumor Microenvironment and Metabolism in Prostate Cancer. Seminars in Oncology, 2014, 41, 267-280.	0.8	58
614	In vitro modeling of the prostate cancer microenvironment. Advanced Drug Delivery Reviews, 2014, 79-80, 214-221.	6.6	46
615	Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer. International Journal of Oncology, 2014, 44, 647-654.	1.4	31
618	Intravoxel Incoherent Motion (IVIM) Diffusion Imaging in Prostate Cancer - What Does It Add?. Journal of Computer Assisted Tomography, 2014, 38, 558-564.	0.5	36
619	Evolution: Back to the future to understand and control prostate cancer. Asian Journal of Urology, 2014, 1, 4-11.	0.5	2
620	Analysis of risk factors for prostate cancer patients. International Journal of Medical Engineering and Informatics, 2015, 7, 365.	0.2	2
621	Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis. Scientific Reports, 2015, 5, 14667.	1.6	57

#	ARTICLE	IF	CITATIONS
623	Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study. <i>Asian Journal of Urology</i> , 2015, 2, 224-232.	0.5	6
624	New insights on the association between the prostate cancer and the small DNA tumour virus, BK polyomavirus. <i>Journal of Translational Medicine</i> , 2015, 13, 387.	1.8	9
625	Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue. <i>Prostate</i> , 2015, 75, 1941-1950.	1.2	44
626	Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer. <i>Prostate</i> , 2015, 75, 1831-1843.	1.2	43
627	Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia. <i>Prostate</i> , 2015, 75, 1844-1856.	1.2	18
628	Polyomavirus BK and prostate cancer: a complex interaction of potential clinical relevance. <i>Reviews in Medical Virology</i> , 2015, 25, 366-378.	3.9	21
629	INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival. <i>Prostate</i> , 2015, 75, 92-102.	1.2	24
630	Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate. <i>Prostate</i> , 2015, 75, 1074-1084.	1.2	11
631	Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. <i>Prostate</i> , 2015, 75, 1669-1675.	1.2	14
632	Proinflammatory Cytokines in Prostate Cancer Development and Progression Promoted by High-Fat Diet. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	29
633	Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice. <i>Journal of Veterinary Science</i> , 2015, 16, 281.	0.5	2
634	Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients. <i>Canadian Urological Association Journal</i> , 2015, 9, 761.	0.3	33
635	Molecular docking analysis of known flavonoids as dual COX-2 inhibitors in the context of cancer. <i>Bioinformatics</i> , 2015, 11, 543-549.	0.2	14
636	An epidemiological analysis of potential associations between C-reactive protein, inflammation, and prostate cancer in the male US population using the 2009-2010 National Health and Nutrition Examination Survey (NHANES) data. <i>Frontiers in Chemistry</i> , 2015, 3, 55.	1.8	10
637	Immune Infiltration and Prostate Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 128.	1.3	161
638	Construction and analysis of lncRNA-lncRNA synergistic networks to reveal clinically relevant lncRNAs in cancer. <i>Oncotarget</i> , 2015, 6, 25003-25016.	0.8	39
639	Prostate Field Cancerization: Deregulated Expression of Macrophage Inhibitory Cytokine 1 (MIC-1) and Platelet Derived Growth Factor A (PDGF-A) in Tumor Adjacent Tissue. <i>PLoS ONE</i> , 2015, 10, e0119314.	1.1	25
640	Genetic Variations in Inflammatory Response Genes and Their Association with the Risk of Prostate Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	8

#	ARTICLE	IF	CITATIONS
641	Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	23
642	Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis. <i>Epidemiology and Health</i> , 2015, 37, e2015005.	0.8	36
644	Prenatal exposure to testosterone masculinises the female gerbil and promotes the development of lesions in the prostate (Skene's gland). <i>Reproduction, Fertility and Development</i> , 2015, 27, 1000.	0.1	25
645	The Prognostic Significance of CXCL16 and Its Receptor C-X-C Chemokine Receptor 6 in Prostate Cancer. <i>American Journal of Pathology</i> , 2015, 185, 2722-2730.	1.9	27
646	Beneficial effect of T follicular helper cells on antibody class switching of B cells in prostate cancer. <i>Oncology Reports</i> , 2015, 33, 1512-1518.	1.2	16
647	Tomato Paste Alters NF- κ B and Cancer-Related mRNA Expression in Prostate Cancer Cells, Xenografts, and Xenograft Microenvironment. <i>Nutrition and Cancer</i> , 2015, 67, 305-315.	0.9	27
648	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. <i>International Journal of Cancer</i> , 2015, 137, 949-958.	2.3	17
649	Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer. <i>British Journal of Cancer</i> , 2015, 112, 755-764.	2.9	62
650	Chronic inflammatory mediators enhance prostate cancer development and progression. <i>Biochemical Pharmacology</i> , 2015, 94, 53-62.	2.0	46
651	Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β 2. <i>Molecular Carcinogenesis</i> , 2015, 54, 730-741.	1.3	32
652	Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. <i>Cancer Causes and Control</i> , 2015, 26, 35-44.	0.8	8
653	Inflammation and prostate cancer: friends or foe?. <i>Inflammation Research</i> , 2015, 64, 275-286.	1.6	48
654	The association between prostate cancer and mood disorders: a nationwide population-based study in Taiwan. <i>International Psychogeriatrics</i> , 2015, 27, 481-490.	0.6	10
655	A Nanoparticle Cocktail: Temporal Release of Predefined Drug Combinations. <i>Journal of the American Chemical Society</i> , 2015, 137, 8324-8327.	6.6	80
656	Highlights of the University of Toronto Urology Update 2014. <i>Canadian Urological Association Journal</i> , 2015, 9, 3.	0.3	0
657	A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1175-1184.	1.6	38
658	Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2015, 8, 590-596.	0.7	11
659	SIGIRR/TIR8, an important regulator of TLR4 and IL-1 α -mediated NF- κ B activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas. <i>Human Pathology</i> , 2015, 46, 1744-1751.	1.1	8

#	ARTICLE	IF	CITATIONS
660	The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. <i>Carcinogenesis</i> , 2015, 36, S128-S159.	1.3	40
661	Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F1421-F1430.	1.3	14
662	A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 242-248.	2.0	49
663	Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 152, 89-100.	1.2	21
664	The effect of pomegranate fruit extract on testosterone-induced BPH in rats. <i>Prostate</i> , 2015, 75, 679-692.	1.2	38
665	The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. <i>Cancer Causes and Control</i> , 2015, 26, 821-830.	0.8	19
666	A Perspective on Prostate Carcinogenesis and Chemoprevention. <i>Current Pharmacology Reports</i> , 2015, 1, 258-265.	1.5	12
667	Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals. <i>Molecular Cancer</i> , 2015, 14, 16.	7.9	32
668	Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2015, 112, 1340-1348.	2.9	48
669	TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells. <i>Prostate</i> , 2015, 75, 1020-1033.	1.2	41
670	Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e217-e221.	0.9	13
671	Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. <i>Autophagy</i> , 2015, 11, 2102-2113.	4.3	27
672	Epithelial and stromal alterations in prostate after cypermethrin administration in adult albino rats (histological and biochemical study). <i>Tissue and Cell</i> , 2015, 47, 366-372.	1.0	8
673	Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 1455-1464.	1.5	11
674	Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 424.e17-424.e23.	0.8	10
675	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	2.7	30
676	Molecular Updates in Prostate Cancer. <i>Surgical Pathology Clinics</i> , 2015, 8, 561-580.	0.7	7
677	Smoking and Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2015, 1, 28-38.	1.6	41

#	ARTICLE	IF	CITATIONS
678	Linking obesogenic dysregulation to prostate cancer progression. <i>Endocrine Connections</i> , 2015, 4, R68-R80.	0.8	30
679	Modeling metabolism: A window toward a comprehensive interpretation of networks in cancer. <i>Seminars in Cancer Biology</i> , 2015, 30, 79-87.	4.3	26
680	A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. <i>Journal of Pathology</i> , 2015, 235, 478-489.	2.1	70
681	DNA damage response and prostate cancer: defects, regulation and therapeutic implications. <i>Oncogene</i> , 2015, 34, 2815-2822.	2.6	81
682	Key Genes in Prostate Cancer Progression: Role of MDM2, PTEN, and TMPRSS2-ERG Fusions. , 2016, , .		0
683	Level-1 Data From the REDUCE Study and the PCPT Data. , 2016, , 199-203.		0
684	Prostatic calculi detected in peripheral zone of the gland during a transrectal ultrasound biopsy can be significant predictors of prostate cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2016, 88, 304.	0.4	9
685	The relationship between histological prostatitis and lower urinary tract symptoms and sexual function. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 540-545.	0.7	8
686	Inflammation and Infection in the Etiology of Prostate Cancer. , 2016, , 13-20.		5
687	The mouse prostate: a basic anatomical and histological guideline. <i>Bosnian Journal of Basic Medical Sciences</i> , 2016, 16, 8-13.	0.6	61
688	Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. <i>Oncotarget</i> , 2016, 7, 44478-44491.	0.8	49
689	Wogonoside prevents colitis-associated colorectal carcinogenesis and colon cancer progression in inflammation-related microenvironment via inhibiting NF- κ B activation through PI3K/Akt pathway. <i>Oncotarget</i> , 2016, 7, 34300-34315.	0.8	42
690	High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-17.	1.9	29
691	From Inflammation to Prostate Cancer: The Role of Inflammasomes. <i>Advances in Urology</i> , 2016, 2016, 1-5.	0.6	50
692	Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. <i>Frontiers in Immunology</i> , 2016, 7, 53.	2.2	33
693	Corpora Amylacea of Brain Tissue from Neurodegenerative Diseases Are Stained with Specific Antifungal Antibodies. <i>Frontiers in Neuroscience</i> , 2016, 10, 86.	1.4	59
694	Cancer Risk and Eicosanoid Production: Interaction between the Protective Effect of Long Chain Omega-3 Polyunsaturated Fatty Acid Intake and Genotype. <i>Journal of Clinical Medicine</i> , 2016, 5, 25.	1.0	19
695	<i>Anisakis pegreffii</i> (Nematoda: Anisakidae) products modulate oxidative stress and apoptosis-related biomarkers in human cell lines. <i>Parasites and Vectors</i> , 2016, 9, 607.	1.0	39

#	ARTICLE	IF	CITATIONS
696	Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms. PLoS ONE, 2016, 11, e0156918.	1.1	43
697	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. PLoS ONE, 2016, 11, e0158952.	1.1	45
698	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Frontiers in Pharmacology, 2016, 7, 376.	1.6	127
699	Association between TLR-9 polymorphisms and colon cancer susceptibility in Saudi Arabian female patients. OncoTargets and Therapy, 2016, Volume 10, 1-11.	1.0	14
700	Gestational and lactational exposition to Di-n-butyl-phthalate (DBP) increases inflammation and preneoplastic lesions in prostate of wistar rats after carcinogenic-methyl-nitrosourea (MNU) plus testosterone protocol. Environmental Toxicology, 2016, 31, 1185-1195.	2.1	24
701	Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate, 2016, 76, 552-564.	1.2	21
702	Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate, 2016, 76, 565-574.	1.2	5
703	Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer. Prostate, 2016, 76, 1192-1202.	1.2	27
704	Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population. International Journal of Cancer, 2016, 139, 1493-1500.	2.3	73
705	Role of the TNF receptor type 1 on prostate carcinogenesis in knockout mice. Prostate, 2016, 76, 917-926.	1.2	11
707	Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Reports, 2016, 17, 2596-2606.	2.9	94
708	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. Cell Reports, 2016, 17, 2620-2631.	2.9	68
709	Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. Journal of Inflammation, 2016, 13, 35.	1.5	52
711	Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer, 2016, 16, 407.	1.1	24
712	miR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression. Oncology Reports, 2016, 35, 2859-2865.	1.2	27
713	The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells. Immunity, 2016, 44, 1177-1189.	6.6	162
714	Inflammation, Microbiota, and Prostate Cancer. European Urology Focus, 2016, 2, 374-382.	1.6	40
715	Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nature Reviews Urology, 2016, 13, 613-626.	1.9	155

#	ARTICLE	IF	CITATIONS
716	Detection of <i>Trichomonas vaginalis</i> in prostate tissue and serostatus in patients with asymptomatic benign prostatic hyperplasia. <i>BMC Infectious Diseases</i> , 2016, 16, 506.	1.3	15
717	Overview on Oxidative Stress, Inflammation, Cancer Initiation/Progression, and How to Prevent Carcinogenesis/Cancer. , 2016, , 26-43.		0
718	Sex steroid-induced DNA methylation changes and inflammation response in prostate cancer. <i>Cytokine</i> , 2016, 86, 110-118.	1.4	16
719	Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>BJU International</i> , 2016, 117, 145-154.	1.3	14
720	A novel anticancer agent icaritin inhibited proinflammatory cytokines in TRAMP mice. <i>International Urology and Nephrology</i> , 2016, 48, 1649-1655.	0.6	9
721	Diversity of Bacterial Urine and Prostate Gland Tissue Cultures in Patients Undergoing Transurethral Prostate Gland Resection. <i>Urologia Internationalis</i> , 2016, 97, 336-339.	0.6	6
722	Association and regulation of protein factors of field effect in prostate tissues. <i>International Journal of Oncology</i> , 2016, 49, 1541-1552.	1.4	15
723	Inflammation and focal atrophy in prostate needle biopsy cores and association to prostatic adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2016, 24, 55-61.	0.6	14
724	The role of prostate inflammation and fibrosis in lower urinary tract symptoms. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F817-F821.	1.3	54
725	Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies. <i>Prostate</i> , 2016, 76, 1501-1506.	1.2	16
726	Association between allergic conditions and risk of prostate cancer: A Prisma-Compliant Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 35682.	1.6	9
728	Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy. <i>Current Urology</i> , 2016, 9, 82-92.	0.4	9
729	The role of the prostate in male fertility, health and disease. <i>Nature Reviews Urology</i> , 2016, 13, 379-386.	1.9	115
730	First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN). <i>EPMA Journal</i> , 2016, 7, 5.	3.3	17
731	Molecular and genetic inflammation networks in major human diseases. <i>Molecular BioSystems</i> , 2016, 12, 2318-2341.	2.9	49
732	Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies <i>DGAT2</i> as a new target gene. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 661-673.	1.5	5
733	Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate. <i>Prostate</i> , 2016, 76, 722-734.	1.2	8
734	A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 323-332.	2.0	20

#	ARTICLE	IF	CITATIONS
735	Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. <i>Gut</i> , 2016, 65, 278-285.	6.1	67
736	Estrogen receptor β in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment. <i>Molecular Cancer</i> , 2016, 15, 7.	7.9	47
737	Integrated analysis of the prostate cancer small nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. <i>Molecular Oncology</i> , 2016, 10, 693-703.	2.1	48
738	Lycopene acts through inhibition of $\text{I}\kappa\text{B}$ kinase to suppress NF- κB signaling in human prostate and breast cancer cells. <i>Tumor Biology</i> , 2016, 37, 9375-9385.	0.8	65
739	Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 729-738.	1.8	7
740	The Surgical Anatomy of the Prostate. , 2016, , 253-263.		2
741	Interferon α microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis. <i>Gut</i> , 2016, 65, 1186-1201.	6.1	47
742	Computational prediction of <i>Mycoplasma hominis</i> proteins targeting in nucleus of host cell and their implication in prostate cancer etiology. <i>Tumor Biology</i> , 2016, 37, 10805-10813.	0.8	28
743	Vitamin D in Prostate Cancer. <i>Vitamins and Hormones</i> , 2016, 100, 321-355.	0.7	21
744	SNAIL transcription factor increases the motility and invasive capacity of prostate cancer cells. <i>Molecular Medicine Reports</i> , 2016, 13, 778-786.	1.1	40
745	Regulation of prostate cancer progression by the tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 340-348.	3.2	166
746	Anti-inflammatory therapies in TRAMP mice: delay in PCa progression. <i>Endocrine-Related Cancer</i> , 2016, 23, 235-250.	1.6	26
747	The molecular and cellular origin of human prostate cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 1238-1260.	1.9	92
748	Principles of Cancer Genetics. , 2016, , .		12
749	The Genetic Basis of Cancer. , 2016, , 1-46.		0
750	Diffusion-weighted MR imaging of pancreatic cancer and inflammation: Prognostic significance of pancreatic inflammation in pancreatic cancer patients. <i>Pancreatology</i> , 2016, 16, 121-126.	0.5	19
751	Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case α control study. <i>World Journal of Urology</i> , 2016, 34, 425-430.	1.2	17
752	Coffee inhibits nuclear factor-kappa B in prostate cancer cells and xenografts. <i>Journal of Nutritional Biochemistry</i> , 2016, 27, 153-163.	1.9	15

#	ARTICLE	IF	CITATIONS
753	Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. <i>Oncogene</i> , 2017, 36, 687-699.	2.6	147
754	Androgen regulation of host defenses and response to inflammatory stimuli in the prostate gland. <i>Cell Biology International</i> , 2017, 41, 1223-1233.	1.4	13
755	Endogenous DNA Damage as a Source of Genomic Instability in Cancer. <i>Cell</i> , 2017, 168, 644-656.	13.5	972
756	Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia. <i>Cancer Medicine</i> , 2017, 6, 730-738.	1.3	16
757	Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 1078-1090.	2.5	23
758	Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-inflammatory Mediators in Chemoprevention of Prostatic Disorders. <i>Prostate</i> , 2017, 77, 838-848.	1.2	10
759	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 711-715.	1.4	12
760	The Microbiome of the Prostate Tumor Microenvironment. <i>European Urology</i> , 2017, 72, 625-631.	0.9	154
761	Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 328-333.	2.0	28
762	The mongolian gerbil (<i>Meriones unguiculatus</i>) as a model for inflammation-promoted prostate carcinogenesis. <i>Cell Biology International</i> , 2017, 41, 1234-1238.	1.4	9
763	The common parasite <i>Toxoplasma gondii</i> induces prostatic inflammation and microglandular hyperplasia in a mouse model. <i>Prostate</i> , 2017, 77, 1066-1075.	1.2	15
764	The Notch-1 receptor in prostate tumorigenesis. <i>Cancer Treatment Reviews</i> , 2017, 56, 36-46.	3.4	25
765	Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. <i>Cancer Prevention Research</i> , 2017, 10, 319-326.	0.7	23
766	The role of prostatic inflammation in the development and progression of benign and malignant diseases. <i>Current Opinion in Urology</i> , 2017, 27, 99-106.	0.9	54
767	Nanomedicine for prostate cancer using nanoemulsion: A review. <i>Journal of Controlled Release</i> , 2017, 260, 111-123.	4.8	38
768	TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. <i>Journal of Leukocyte Biology</i> , 2017, 102, 423-436.	1.5	47
769	Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 933-944.	2.3	44
770	Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. <i>Journal of Leukocyte Biology</i> , 2017, 102, 393-406.	1.5	55

#	ARTICLE	IF	CITATIONS
771	Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 167-175.	3.3	22
772	Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. <i>Oncogene</i> , 2017, 36, 4597-4609.	2.6	35
773	Identification of Filamin-A and -B as potential biomarkers for prostate cancer. <i>Future Science OA</i> , 2017, 3, FSO161.	0.9	20
774	Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 845-853.	1.1	52
775	Gamma-glutamyltransferase and risk of prostate cancer: Findings from the KIH prospective cohort study. <i>International Journal of Cancer</i> , 2017, 140, 818-824.	2.3	14
776	Cancer and inflammation. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2017, 9, e1370.	6.6	166
777	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.1	6
779	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 253-271.	0.1	2
780	CXXC5 expression in prostate cancer: implications for cancer progression. <i>International Journal of Experimental Pathology</i> , 2017, 98, 234-243.	0.6	7
781	Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. <i>Cancer Medicine</i> , 2017, 6, 2461-2470.	1.3	48
782	Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry. <i>Cancer Causes and Control</i> , 2017, 28, 1313-1321.	0.8	8
783	Desquamation takes center stage at the origin of proliferative inflammatory atrophy, epithelial-mesenchymal transition, and stromal growth in benign prostate hyperplasia. <i>Cell Biology International</i> , 2017, 41, 1265-1270.	1.4	4
784	Inflammatory reaction found in prostate-specific material method standardization and proposed optimal cutoff points. <i>Andrology</i> , 2017, 5, 958-963.	1.9	6
785	A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1549-1557.	1.1	61
786	Concomitant bladder cancer and prostate cancer: challenges and controversies. <i>Nature Reviews Urology</i> , 2017, 14, 620-629.	1.9	17
787	A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. <i>Scientific Reports</i> , 2017, 7, 15624.	1.6	27
788	Identification of low oxygen-tolerating bacteria in prostate secretions of cancer patients and discussion of possible aetiological significance. <i>Scientific Reports</i> , 2017, 7, 15164.	1.6	5
789	Telomeres and telomerase in prostate cancer development and therapy. <i>Nature Reviews Urology</i> , 2017, 14, 607-619.	1.9	85

#	ARTICLE	IF	CITATIONS
790	Resveratrol and pterostilbene as a microRNA-mediated chemopreventive and therapeutic strategy in prostate cancer. <i>Annals of the New York Academy of Sciences</i> , 2017, 1403, 15-26.	1.8	44
791	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6764-6770.	3.2	173
792	<i>Trichomonas vaginalis</i> infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial. <i>Cancer Causes and Control</i> , 2017, 28, 889-898.	0.8	25
793	Epidemiology of Prostate Cancer. , 2017, , 107-125.		3
794	Adipocytokines, Energy Balance, and Cancer. <i>Energy Balance and Cancer</i> , 2017, , .	0.2	4
795	Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw225.	3.0	62
796	Stromal factors involved in human prostate cancer development, progression and castration resistance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 351-359.	1.2	41
797	Cell cycle-coupled expansion of AR activity promotes cancer progression. <i>Oncogene</i> , 2017, 36, 1655-1668.	2.6	32
798	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 123-144.	1.2	6
799	Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence. <i>Prostate</i> , 2017, 77, 412-424.	1.2	43
800	Ecotropic viral integration site 1, a novel oncogene in prostate cancer. <i>Oncogene</i> , 2017, 36, 1573-1584.	2.6	29
801	Intraprostatic Chronic Inflammation is Associated with a Reduced Risk of Prostate Cancer in Patients Elected to a First Random Biopsy Set. <i>Tumori</i> , 2017, 103, 475-482.	0.6	10
802	1 Introduction to Prostate Cancer: Clinical Considerations. , 2017, , .		0
803	Infection by Human Papillomavirus (HPV), <i>Chlamydia trachomatis</i> and <i>Ureaplasma urealyticum</i> , in Relation with Reproductive Failure. , 0, , .		1
804	Evaluation of inflammatory cytokines and oxidative stress markers in prostate cancer patients undergoing curative radiotherapy. <i>Central-European Journal of Immunology</i> , 2017, 1, 68-72.	0.4	10
805	Glucose Metabolism in the Progression of Prostate Cancer. <i>Frontiers in Physiology</i> , 2017, 8, 97.	1.3	98
806	5.17 Three-Dimensional Bioengineered Cancer Models. , 2017, , 303-328.		2
807	Natriuretic Peptides: The Case of Prostate Cancer. <i>Molecules</i> , 2017, 22, 1680.	1.7	9

#	ARTICLE	IF	CITATIONS
808	Prevalence of Flp Pili-Encoding Plasmids in Cutibacterium acnes Isolates Obtained from Prostatic Tissue. <i>Frontiers in Microbiology</i> , 2017, 8, 2241.	1.5	21
809	Chemopreventive Strategies for Inflammation-Related Carcinogenesis: Current Status and Future Direction. <i>International Journal of Molecular Sciences</i> , 2017, 18, 867.	1.8	23
810	Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth. <i>BMC Cancer</i> , 2017, 17, 878.	1.1	52
811	Exosomes in diagnosis and therapy of prostate cancer. <i>Oncotarget</i> , 2017, 8, 97693-97700.	0.8	73
812	Prenatal and pubertal testosterone exposure imprint permanent modifications in the prostate that predispose to the development of lesions in old Mongolian gerbils. <i>Asian Journal of Andrology</i> , 2017, 19, 160.	0.8	11
813	MicroRNA expression profiling in canine prostate cancer. <i>Journal of Veterinary Medical Science</i> , 2017, 79, 719-725.	0.3	25
814	Association between interleukin-18 variants and prostate cancer in Slovak population. <i>Neoplasma</i> , 2017, 64, 148-155.	0.7	15
815	Racial disparities in prostate cancer a molecular perspective. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 772-782.	3.0	87
816	Clinical implications of PTEN loss in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 222-234.	1.9	408
818	Celecoxib-Induced Self-Assembly of Smart Albumin-Doxorubicin Conjugate for Enhanced Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 8555-8565.	4.0	36
819	A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity. <i>Molecular Pharmaceutics</i> , 2018, 15, 1724-1728.	2.3	34
820	Tumor-associated myeloid cells promote tumorigenesis of non-tumorigenic human and murine prostatic epithelial cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 873-883.	2.0	5
821	Abiraterone acetate in the treatment of prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2018, 101, 211-218.	2.5	51
822	Nitric oxide donors for prostate and bladder cancers: Current state and challenges. <i>European Journal of Pharmacology</i> , 2018, 826, 158-168.	1.7	27
823	Viral etiology of prostate cancer: Genetic alterations and immune response. A literature review. <i>International Journal of Surgery</i> , 2018, 52, 136-140.	1.1	20
824	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e1-240.e11.	0.8	20
825	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 783-789.	1.1	1
826	Proliferation of prostate epithelia induced by <i>IL-6</i> from stroma reacted with <i>Trichomonas vaginalis</i> . <i>Parasite Immunology</i> , 2018, 40, e12531.	0.7	12

#	ARTICLE	IF	CITATIONS
827	Molecular and Therapeutic actions of Thymoquinone. , 2018, , .		6
828	Cycloartane-type sapogenol derivatives inhibit NF κ B activation as chemopreventive strategy for inflammation-induced prostate carcinogenesis. Steroids, 2018, 135, 9-20.	0.8	8
829	Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamine treatments in TRAMP mice. Cell Biology International, 2018, 42, 1006-1020.	1.4	11
830	Statin use linked with a decrease in the conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer. Carcinogenesis, 2018, 39, 819-825.	1.3	6
831	Molecular Pathogenesis of Prostate Cancer. , 2018, , 555-568.		7
832	Potentiating prostate cancer immunotherapy with oncolytic viruses. Nature Reviews Urology, 2018, 15, 235-250.	1.9	46
833	Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats. Hormones and Cancer, 2018, 9, 175-187.	4.9	6
834	TheÂmolecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer and Prostatic Diseases, 2018, 21, 22-36.	2.0	70
835	Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer and Prostatic Diseases, 2018, 21, 147-152.	2.0	26
836	Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. International Journal of Cancer, 2018, 142, 2254-2262.	2.3	40
837	The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030361.	2.9	461
838	Chemoprevention in Prostate Cancer: Current Perspective and Future Directions. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030494.	2.9	4
839	High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Modern Pathology, 2018, 31, 71-79.	2.9	73
840	Calcium and CaSR/IP3R in prostate cancer development. Cell and Bioscience, 2018, 8, .	2.1	14
841	MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clinical Cancer Research, 2018, 24, 3668-3680.	3.2	56
842	<scp>P</scp>rostatitis, other genitourinary infections and prostate cancer risk: <scp>I</scp>nfluence of nonâ€steroidal antiâ€inflammatory drugs? <scp>R</scp>esults from the <scp>EPICAP</scp> study. International Journal of Cancer, 2018, 143, 1644-1651.	2.3	11
844	Appendicitis before Age 20 Years Is Associated with an Increased Risk of Later Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 660-664.	1.1	2
845	Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes and Control, 2018, 29, 455-464.	0.8	6

#	ARTICLE	IF	CITATIONS
846	The Correlation of Prostate Volume and Prostate-specific Antigen Levels With Positive Bacterial Prostate Tissue Cultures. <i>Urology</i> , 2018, 115, 151-156.	0.5	3
847	Crocetin treatment inhibits proliferation of colon cancer cells through down-regulation of genes involved in the inflammation. <i>Saudi Journal of Biological Sciences</i> , 2018, 25, 1767-1771.	1.8	19
848	Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug. <i>Inorganica Chimica Acta</i> , 2018, 472, 221-228.	1.2	31
849	Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. <i>Prostate</i> , 2018, 78, 2-10.	1.2	124
850	The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. <i>Urology</i> , 2018, 111, 122-128.	0.5	138
851	Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study. <i>Prostate</i> , 2018, 78, 202-212.	1.2	7
852	The inflammatory microenvironment and microbiome in prostate cancer development. <i>Nature Reviews Urology</i> , 2018, 15, 11-24.	1.9	311
853	Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulate the prostatic lesions in a rodent model for prostate cancer. <i>Prostate</i> , 2018, 78, 152-163.	1.2	21
854	Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 161-171.	0.2	188
855	DETECTION OF PROSTATE CANCER: A REVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 25.	0.3	1
856	The Carcinogenic Potential of Microbial Infections of the Prostate and the Role of Contaminations. <i>Translational Biomedicine</i> , 2018, 09, .	0.1	0
857	Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients. <i>Scientific Reports</i> , 2018, 8, 16335.	1.6	23
858	Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11091-E11100.	3.3	19
859	Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate. <i>Journal of Biological Chemistry</i> , 2018, 293, 20123-20136.	1.6	12
860	3D Cell Culture Model for Prostate Cancer Cells to Mimic Inflammatory Microenvironment. <i>Proceedings (mdpi)</i> , 2018, 2, 1555.	0.2	4
861	Intraurethral injection with LPS: an effective experimental model of prostatic inflammation. <i>Inflammation Research</i> , 2018, 67, 43-55.	1.6	22
862	A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra. <i>Cell Reports</i> , 2018, 25, 3530-3542.e5.	2.9	204
863	Implications of prostate inflammation on male fertility. <i>Andrologia</i> , 2018, 50, e13093.	1.0	45

#	ARTICLE	IF	CITATIONS
864	Obesity-Linked Cancers: Current Knowledge, Challenges and Limitations in Mechanistic Studies and Rodent Models. <i>Cancers</i> , 2018, 10, 523.	1.7	17
865	Cooperation of loss of <i>NKX3.1</i> and inflammation in prostate cancer initiation. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	30
866	Genetic Determinants of Cancer Susceptibility. , 2018, , 330-360.		4
867	Association between HPV infection and prostate cancer in a Mexican population. <i>Genetics and Molecular Biology</i> , 2018, 41, 781-789.	0.6	29
868	Targeting Crosstalk between Nrf-2, NF- κ B and Androgen Receptor Signaling in Prostate Cancer. <i>Cancers</i> , 2018, 10, 352.	1.7	64
869	The distribution of BCG prostatitis: A clue for pathogenetic processes?. <i>Prostate</i> , 2018, 78, 1134-1139.	1.2	11
870	Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists. <i>Cell Death and Disease</i> , 2018, 9, 1081.	2.7	14
871	STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5948-5962.	3.2	59
872	Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands. <i>Bioinorganic Chemistry and Applications</i> , 2018, 2018, 1-18.	1.8	54
873	New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2545.	1.8	10
874	Long Non-Coding RNAs in Obesity-Induced Cancer. <i>Non-coding RNA</i> , 2018, 4, 19.	1.3	36
875	A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation. <i>Biomaterials</i> , 2018, 187, 117-129.	5.7	21
876	The microbiome in prostate inflammation and prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 345-354.	2.0	125
877	Do dietary calcium and vitamin D matter in men with prostate cancer?. <i>Nature Reviews Urology</i> , 2018, 15, 453-461.	1.9	18
878	MicroRNAs in prostate cancer: From function to biomarker discovery. <i>Experimental Biology and Medicine</i> , 2018, 243, 817-825.	1.1	18
879	CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel. <i>Oncology Letters</i> , 2018, 16, 1267-1274.	0.8	17
880	An eco-friendly catalytic system for multicomponent, one-pot synthesis of novel spiro-chromeno indoline-triones and their anti-prostate cancer potentials evaluated via alkaline phosphatase inhibition mechanism. <i>Bioorganic Chemistry</i> , 2018, 81, 44-54.	2.0	26
881	Concentrated sugars and incidence of prostate cancer in a prospective cohort. <i>British Journal of Nutrition</i> , 2018, 120, 703-710.	1.2	16

#	ARTICLE	IF	CITATIONS
882	Expression of Indoleamine 2,3-Dioxygenase Induced by IFN- \hat{I}^3 and TNF- \hat{I}^{\pm} as Potential Biomarker of Prostate Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1051.	2.2	63
883	Pathologic Triggers Related to LUTS and BPH. , 2018, , 15-29.		3
884	The Relationship Between Inflammation and LUTS/BPH. , 2018, , 31-50.		2
885	Vitamin D Hormone Action in the Endocrine Tissue: Implications for Prostate and Breast Carcinoma. <i>Contemporary Endocrinology</i> , 2018, , 77-101.	0.3	0
886	To Decipher the <i>Mycoplasma hominis</i> Proteins Targeting into the Endoplasmic Reticulum and Their Implications in Prostate Cancer Etiology Using Next-Generation Sequencing Data. <i>Molecules</i> , 2018, 23, 994.	1.7	14
887	Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. <i>Prostate</i> , 2018, 78, 1172-1180.	1.2	17
888	Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration. <i>Clinical Cancer Research</i> , 2018, 24, 5622-5634.	3.2	77
889	Role of oxidative stress in pathology of chronic prostatitis/chronic pelvic pain syndrome and male infertility and antioxidants function in ameliorating oxidative stress. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 714-723.	2.5	65
890	Association between male accessory gland infections and prostate cancer in Turkish men: A case-control study. <i>Andrologia</i> , 2018, 50, e13038.	1.0	2
891	Ageing and inflammation in the male reproductive tract. <i>Andrologia</i> , 2018, 50, e13034.	1.0	38
892	Sustained influence of infections on prostate-specific antigen concentration: An analysis of changes over 10 years of follow-up. <i>Prostate</i> , 2018, 78, 1024-1034.	1.2	4
893	Vitamin D Inflammation and Cancer. , 2018, , 891-911.		0
894	Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 438-445.	2.0	14
895	Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2018, 81, e39.	4.0	6
896	High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF- \hat{I}^B signaling pathway. <i>International Journal of Oncology</i> , 2018, 53, 659-671.	1.4	39
897	Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030403.	2.9	25
898	<p>Protective effect of Chuquiraga spinosa Lessing associated with simvastatin on N-Nitroso-N-methylurea (NMU)-induced prostate cancer in rats</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6555-6562.	1.0	2
899	Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1153.	1.7	37

#	ARTICLE	IF	CITATIONS
900	Colorectal carcinoma in the course of inflammatory bowel diseases. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 18.	0.6	60
901	Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level. <i>Nutrients</i> , 2019, 11, 1616.	1.7	13
902	Search for Novel Diagnostic Biomarkers of Prostate Inflammation-Related Disorders: Role of Transglutaminase Isoforms as Potential Candidates. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	5
903	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. <i>Scientific Reports</i> , 2019, 9, 10662.	1.6	32
904	Quantitation of Lipid Peroxidation Product DNA Adducts in Human Prostate by Tandem Mass Spectrometry: A Method That Mitigates Artifacts. <i>Chemical Research in Toxicology</i> , 2019, 32, 1850-1862.	1.7	9
905	Microcalcifications, calcium-sensing receptor, and cancer. <i>Cell Calcium</i> , 2019, 82, 102051.	1.1	8
906	CDKN1B Val 109 Gly variant is not related to risk of prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 18346-18356.	1.2	3
907	Serum Urate, Genetic Variation, and Prostate Cancer Risk: Atherosclerosis Risk in Communities (ARIC) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1259-1261.	1.1	5
908	Association of rs1800629 tumor necrosis factor alpha polymorphism with risk of prostate tumors of Iraqi patients. <i>Gene Reports</i> , 2019, 17, 100477.	0.4	1
909	In Search for risk predictors at the microscopic scenario of a negative biopsy. A systematic review. <i>Actas Urológicas Españolas (English Edition)</i> , 2019, 43, 337-347.	0.2	1
910	Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer—A Comprehensive Review. <i>Diagnostics</i> , 2019, 9, 161.	1.3	17
912	The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Future Oncology</i> , 2019, 15, 1469-1479.	1.1	8
913	TGF-Beta in the Natural History of Prostate Cancer. <i>Acta Clinica Croatica</i> , 2019, 58, 128-138.	0.1	19
914	Role of sterile pyuria in association to elevated PSA values in the diagnosis of non-palpable prostate cancer?. <i>Archivio Italiano Di Urologia Andrologia</i> , 2019, 91, .	0.4	2
915	Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. <i>American Journal of Pathology</i> , 2019, 189, 2311-2322.	1.9	13
916	Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis. <i>Prostate</i> , 2019, 79, 1316-1325.	1.2	3
917	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. <i>Molecular Cancer Research</i> , 2019, 17, 1605-1612.	1.5	21
918	The Microbiome in the Prostate: Prostatitis and Prostate Cancer. , 2019, , 125-135.		0

#	ARTICLE	IF	CITATIONS
919	Epidemiology of Prostate Cancer. World Journal of Oncology, 2019, 10, 63-89.	0.6	1,503
920	Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGESâ€œReykjavik study. Cancer, 2019, 125, 2877-2885.	2.0	37
921	Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 173-221.	0.1	3
924	Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistochemistry on prostate cancer tissue microarrays. Laboratory Investigation, 2019, 99, 1527-1534.	1.7	13
925	Implications of the Genitourinary Microbiota in Prostatic Disease. Current Urology Reports, 2019, 20, 34.	1.0	28
926	Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression. Journal of Clinical Medicine, 2019, 8, 597.	1.0	39
927	Chronic prostatitis alters the prostatic microenvironment and accelerates preneoplastic lesions in C57BL/6 mice. Biological Research, 2019, 52, 30.	1.5	6
928	Inflammatory mediators of prostate epithelial cells stimulated with <i>Trichomonas vaginalis</i> promote proliferative and invasive properties of prostate cancer cells. Prostate, 2019, 79, 1133-1146.	1.2	26
929	Prostate cancer biomarkers detection using nanoparticles based electrochemical biosensors. Biosensors and Bioelectronics, 2019, 137, 213-221.	5.3	87
930	Consequences of interleukin 1 β -triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4 ⁺ infiltration mimics human proliferative inflammatory atrophy. Prostate, 2019, 79, 732-745.	1.2	25
931	Metabolic reprogramming links chronic intestinal inflammation and the oncogenic transformation in colorectal tumorigenesis. Cancer Letters, 2019, 450, 123-131.	3.2	12
932	Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer. Investigative and Clinical Urology, 2019, 60, 91.	1.0	9
933	The Human Microbiota and Prostate Cancer: Friend or Foe?. Cancers, 2019, 11, 459.	1.7	38
934	Development of a series of 4-hydroxycoumarin platinum(IV) hybrids as antitumor agents: Synthesis, biological evaluation and action mechanism investigation. Journal of Inorganic Biochemistry, 2019, 194, 34-43.	1.5	17
935	A role for paracrine interleukinâ€œ6 signaling in the tumor microenvironment in prostate tumor growth. Prostate, 2019, 79, 215-222.	1.2	13
936	Obesity, Inflammation, and Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 201.	1.0	92
937	Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice. Prostate, 2019, 79, 515-535.	1.2	8
938	MAJOR BIOACTIVE TRITERPENOIDS FROM GANODERMA SPECIES AND THEIR THERAPEUTIC ACTIVITY: A REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 0, , 22-30.	0.3	9

#	ARTICLE	IF	CITATIONS
939	Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 464.	3.5	42
940	Cells of Origin for Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 67-86.	0.8	20
941	The association between epididymo-orchitis and prostate cancer. <i>Medicine (United States)</i> , 2019, 98, e15363.	0.4	0
942	<p>The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10125-10133.	0.9	10
943	A Systematic Review and Meta-analysis of Associations between Clinical Prostatitis and Prostate Cancer: New Estimates Accounting for Detection Bias. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1594-1603.	1.1	14
944	Downregulation of Pro-Inflammatory and Pro-Angiogenic Pathways in Prostate Cancer Cells by a Polyphenol-Rich Extract from Olive Mill Wastewater. <i>International Journal of Molecular Sciences</i> , 2019, 20, 307.	1.8	36
945	Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins. <i>BMC Cancer</i> , 2019, 19, 61.	1.1	85
946	Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. <i>Cancer Medicine</i> , 2019, 8, 1110-1123.	1.3	69
947	Synthesis of new thiazolo-pyrrolidineâ€“(spirooxindole) tethered to 3-acylindole as anticancer agents. <i>Bioorganic Chemistry</i> , 2019, 82, 423-430.	2.0	66
948	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 32-37.	0.9	4
949	Epsteinâ€“Barr virus and thyroid cancer: The role of viral expressed proteins. <i>Journal of Cellular Physiology</i> , 2019, 234, 3790-3799.	2.0	42
950	Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP Diet and Health Study. <i>International Journal of Epidemiology</i> , 2019, 48, 464-473.	0.9	26
951	Selenium and Sex Steroid Hormones in a U.S. Nationally Representative Sample of Men: A Role for the Link between Selenium and Estradiol in Prostate Carcinogenesis?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 578-583.	1.1	3
952	Tumorâ€“infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?. <i>Prostate</i> , 2019, 79, 320-330.	1.2	58
953	Depression-Induced Neuropeptide Y Secretion Promotes Prostate Cancer Growth by Recruiting Myeloid Cells. <i>Clinical Cancer Research</i> , 2019, 25, 2621-2632.	3.2	54
954	Impact of consumption of repeatedly heated cooking oils on the incidence of various cancers- A critical review. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 488-505.	5.4	56
955	Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU). <i>European Urology Focus</i> , 2019, 5, 756-787.	1.6	52
956	Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. <i>Aging Male</i> , 2020, 23, 132-138.	0.9	24

#	ARTICLE	IF	CITATIONS
957	The prevalence and risk factors of prostatic calculi in Han Chinese: a cross-sectional study based on health examinations. <i>Aging Male</i> , 2020, 23, 887-892.	0.9	7
958	The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 53-58.	2.0	31
959	Inflammatory serum markers and risk and severity of prostate cancer: The PROCAâ€‹i>life</i> study. <i>International Journal of Cancer</i> , 2020, 147, 84-92.	2.3	26
962	Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans. <i>Anticancer Research</i> , 2020, 40, 27-34.	0.5	9
963	PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer. <i>FASEB Journal</i> , 2020, 34, 1304-1318.	0.2	15
964	Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 1243-1258.	2.5	14
965	Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. <i>Prostate</i> , 2020, 80, 336-344.	1.2	7
966	Aberrant activation of hepatocyte growth factor/MET signaling promotes β -cateninâ€‹mediated prostatic tumorigenesis. <i>Journal of Biological Chemistry</i> , 2020, 295, 631-644.	1.6	6
967	Modified simple prostatectomy: an approach to address large volume BPH and associated prostate cancers. <i>Journal of Robotic Surgery</i> , 2020, 14, 543-548.	1.0	6
968	Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 753-761.	1.0	7
969	The association between HPV gene expression, inflammatory agents and cellular genes involved in EMT in lung cancer tissue. <i>BMC Cancer</i> , 2020, 20, 916.	1.1	20
970	Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate. <i>Cells</i> , 2020, 9, 2153.	1.8	2
971	Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. <i>Cancers</i> , 2020, 12, 2984.	1.7	69
972	The silent presence of <i>Mycoplasma hominis</i> in patients with prostate cancer. <i>Pathogens and Disease</i> , 2020, 78, .	0.8	13
973	The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. <i>Cancers</i> , 2020, 12, 1887.	1.7	76
974	Inflammatory bowel disease and prostate cancer risk: A systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 207-212.	0.7	9
975	Liquid Biopsy to Detect DNA/RNA Based Markers of Small DNA Oncogenic Viruses for Prostate Cancer Diagnosis, Prognosis, and Prediction. <i>Frontiers in Oncology</i> , 2020, 10, 778.	1.3	10
976	Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21576-21587.	3.3	48

#	ARTICLE	IF	CITATIONS
977	Modulation of complement activation by pentraxin-3 in prostate cancer. <i>Scientific Reports</i> , 2020, 10, 18400.	1.6	15
978	The role of viruses in adenocarcinoma development. <i>Infection, Genetics and Evolution</i> , 2020, 86, 104603.	1.0	6
979	Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision-making processes. <i>Cancer Medicine</i> , 2020, 9, 7524-7536.	1.3	5
980	Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men. <i>Prostate</i> , 2020, 80, 1365-1372.	1.2	2
981	Assessment of urinary 15-keto- Δ^8 -isoprostanes in dogs with urothelial carcinoma of the urinary bladder and other lower urinary tract diseases. <i>Journal of Veterinary Internal Medicine</i> , 2020, 34, 2454-2459.	0.6	1
982	Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). <i>Prostate</i> , 2020, 80, 1429-1437.	1.2	11
983	Influence of Intratumor Microbiome on Clinical Outcome and Immune Processes in Prostate Cancer. <i>Cancers</i> , 2020, 12, 2524.	1.7	40
984	Application of Anti-Inflammatory Agents in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2680.	1.0	12
985	Genetically Predicted Circulating Level of C-Reactive Protein Is Not Associated With Prostate Cancer Risk. <i>Frontiers in Oncology</i> , 2020, 10, 545603.	1.3	6
986	A Prostate MRI Segmentation Tool Based on Active Contour Models Using a Gradient Vector Flow. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6163.	1.3	5
987	Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers. <i>Mediators of Inflammation</i> , 2020, 2020, 1-11.	1.4	16
988	Prostate carcinogenesis: inflammatory storms. <i>Nature Reviews Cancer</i> , 2020, 20, 455-469.	12.8	114
989	Epstein-Barr and BK virus in cancerous and noncancerous prostate tissue. <i>Future Virology</i> , 2020, 15, 13-17.	0.9	3
990	Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	0.9	9
991	The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial. <i>Prostate</i> , 2020, 80, 895-905.	1.2	0
992	The human gastrointestinal microbiota and prostate cancer development and treatment. <i>Investigative and Clinical Urology</i> , 2020, 61, S43.	1.0	36
993	Cancer Microbiomatics?. , 2020, , 203-224.		1
994	Metabolically Abnormal Obesity Increases the Risk of Advanced Prostate Cancer in Chinese Patients Undergoing Radical Prostatectomy. <i>Cancer Management and Research</i> , 2020, Volume 12, 1779-1787.	0.9	5

#	ARTICLE	IF	CITATIONS
995	Body mass index trajectories and prostate cancer risk: Results from the EPICAP study. <i>Cancer Medicine</i> , 2020, 9, 6421-6429.	1.3	19
996	Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2020, 13, 853-862.	0.7	8
997	Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. <i>Medicina (Lithuania)</i> , 2020, 56, 285.	0.8	11
998	Blood platelets stimulate cancer extravasation through TGF β 2-mediated downregulation of PRH/HHEX. <i>Oncogenesis</i> , 2020, 9, 10.	2.1	27
999	From Ancient to Emerging Infections: The Odyssey of Viruses in the Male Genital Tract. <i>Physiological Reviews</i> , 2020, 100, 1349-1414.	13.1	77
1000	Increased estrogen levels altered microRNA expression in prostate and plasma of rats dosed with sex hormones. <i>Andrology</i> , 2020, 8, 1360-1374.	1.9	9
1001	Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 600.e9-600.e15.	0.8	15
1002	IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 153-165.	1.5	58
1003	Expression and Prognostic Value of IFIT1 and IFITM3 in Head and Neck Squamous Cell Carcinoma. <i>American Journal of Clinical Pathology</i> , 2020, 153, 618-629.	0.4	15
1004	Increased Preoperative Plasma Level of Microbial 16S rDNA Translocation Is Associated With Relapse After Prostatectomy in Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1532.	1.3	5
1005	Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities. <i>Seminars in Cancer Biology</i> , 2022, 80, 39-57.	4.3	74
1006	Ultrasmall Rhodium Nanozyme with RONS Scavenging and Photothermal Activities for Anti-Inflammation and Antitumor Theranostics of Colon Diseases. <i>Nano Letters</i> , 2020, 20, 3079-3089.	4.5	121
1007	The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 794.e17-794.e27.	0.8	2
1008	Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer. <i>Prostate</i> , 2020, 80, 687-697.	1.2	3
1009	Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-12.	1.9	14
1010	High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 668-675.	1.1	16
1011	No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor- β gene and susceptibility to prostate cancer: a comprehensive meta-analysis. <i>Hereditas</i> , 2020, 157, 11.	0.5	2
1012	Human microbiome and prostate cancer development: current insights into the prevention and treatment. <i>Frontiers of Medicine</i> , 2021, 15, 11-32.	1.5	17

#	ARTICLE	IF	CITATIONS
1013	Genomic and phenotypic heterogeneity in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 79-92.	1.9	215
1014	Chronic exposure to microcystin-LR increases the risk of prostate cancer and induces malignant transformation of human prostate epithelial cells. <i>Chemosphere</i> , 2021, 263, 128295.	4.2	29
1015	Carcinogenesis: Failure of resolution of inflammation?. , 2021, 218, 107670.		101
1016	Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. <i>Nutrition and Cancer</i> , 2021, , 1-8.	0.9	2
1017	Validation of the Effectiveness of Neutrophil-to-lymphocyte Ratio (NLR) as a Predictive Factor in Patients Undergoing Prostate Biopsy With Prostate Specific Antigen (PSA) Between 4.0 and 10.0 ng/ml. <i>In Vivo</i> , 2021, 35, 1641-1646.	0.6	4
1018	In Vivo Models for Obesity and Obesity Related Carcinogenesis. , 2021, , 279-300.		2
1019	Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors. <i>Frontiers in Immunology</i> , 2020, 11, 586126.	2.2	40
1020	The multiple effects of aspirin in prostate cancer patients. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100267.	0.7	12
1021	Why Do Epidemiologic Studies Find an Inverse Association Between Intraprostatic Inflammation and Prostate Cancer: A Possible Role for Colliding Bias?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 255-259.	1.1	4
1022	Prostate Carcinogenesis: Insights in Relation to Epigenetics and Inflammation. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 253-267.	0.6	11
1023	Phytochemistry, pharmacodynamics, and pharmacokinetics of a classic Chinese herbal formula Danggui Beimu Kushen Wan: A review. <i>Phytotherapy Research</i> , 2021, 35, 3673-3689.	2.8	3
1024	Cardiorespiratory fitness is not associated with reduced risk of prostate cancer: A cohort study and review of the literature. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13545.	1.7	3
1025	INPP4B protects from metabolicÂsyndrome and associated disorders. <i>Communications Biology</i> , 2021, 4, 416.	2.0	10
1026	Experimental Chronic Prostatitis/Chronic Pelvic Pain Syndrome Increases Anxiety-Like Behavior: The Role of Brain Oxidative Stress, Serum Corticosterone, and Hippocampal Parvalbumin-Positive Interneurons. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-17.	1.9	19
1027	Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development. <i>Frontiers in Genetics</i> , 2021, 12, 652747.	1.1	42
1028	Herb-target virtual screening and network pharmacology for prediction of molecular mechanism of Danggui Beimu Kushen Wan for prostate cancer. <i>Scientific Reports</i> , 2021, 11, 6656.	1.6	18
1029	Mast Cell-Derived SAMD14 Is a Novel Regulator of the Human Prostate Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 1237.	1.7	10
1030	Human Prostate Epithelial Cells Activate the AIM2 Inflammasome upon Cellular Senescence: Role of POP3 Protein in Aging-Related Prostatic Inflammation. <i>Life</i> , 2021, 11, 366.	1.1	10

#	ARTICLE	IF	CITATIONS
1031	Morphological and Molecular Characterization of Proliferative Inflammatory Atrophy in Canine Prostatic Samples. <i>Cancers</i> , 2021, 13, 1887.	1.7	6
1032	The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapy. <i>Andrologia</i> , 2021, 53, e14070.	1.0	1
1033	Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4109.	1.8	15
1034	Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS). <i>Aging</i> , 2021, 13, 10934-10954.	1.4	32
1035	NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation. <i>Cancer Discovery</i> , 2021, 11, 2316-2333.	7.7	25
1036	Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis. <i>Frontiers in Surgery</i> , 2021, 8, 636791.	0.6	6
1037	Sleep disorders and prostate cancer prognosis. <i>European Journal of Cancer Prevention</i> , 2021, Publish Ahead of Print, .	0.6	3
1038	Can we use neutrophil to lymphocyte ratio in the diagnosis and prediction of extracapsular extension in localized prostate cancer?. <i>Urologia</i> , 2021, , 039156032110148.	0.3	0
1039	GPR30 knockdown weakens the capacity of CAF in promoting prostate cancer cell invasion via reducing macrophage infiltration and M2 polarization. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 1173-1191.	1.2	19
1040	Progenitors in prostate development and disease. <i>Developmental Biology</i> , 2021, 473, 50-58.	0.9	10
1041	Interleukin-13 rs1800925/-1112C/T promoter single nucleotide polymorphism variant linked to anti-schistosomiasis in adult males in Murehwa District, Zimbabwe. <i>PLoS ONE</i> , 2021, 16, e0252220.	1.1	4
1042	Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy. <i>Analytical Cellular Pathology</i> , 2021, 2021, 1-15.	0.7	17
1043	Prostatic Inflammation in Prostate Cancer: Protective Effect or Risk Factor?. <i>Uro</i> , 2021, 1, 54-59.	0.3	4
1044	Novel insights in cell cycle dysregulation during prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2021, 28, R141-R155.	1.6	16
1045	Modern Approaches to Treatment of Abacterial Prostatitis and Benign Prostate Hyperplasia Using a Prostate Extract of Bulls. <i>Health of Man</i> , 2021, , 32-37.	0.1	0
1047	GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. <i>PLoS ONE</i> , 2021, 16, e0241934.	1.1	14
1048	MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. <i>Cancer Research</i> , 2021, 81, 4471-4484.	0.4	5
1049	Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?. <i>Anticancer Research</i> , 2021, 41, 3067-3073.	0.5	7

#	ARTICLE	IF	CITATIONS
1050	Theoretical Substantiation of the Use of Sildenafil in the Treatment of Chronic Prostatitis. <i>Health of Man</i> , 2021, , 58-62.	0.1	0
1052	An overview of the latest in state-of-the-art murine models for prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1349-1364.	2.5	3
1053	Cellular senescence as a possible link between prostate diseases of the ageing male. <i>Nature Reviews Urology</i> , 2021, 18, 597-610.	1.9	19
1054	Prevalence of Human Polyomavirus BK Virus in Prostate Cancer Patients and Benign Prostatic Hyperplasia: A Cross-sectional Study on Prostate Patients Referred to Imam Khomeini Hospital in Ahvaz Between 2015 and 2017. <i>Jundishapur Journal of Microbiology</i> , 2021, 14, .	0.2	0
1055	Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer. <i>BMC Cancer</i> , 2021, 21, 926.	1.1	22
1056	Urinary PGE-M in Men with Prostate Cancer. <i>Cancers</i> , 2021, 13, 4073.	1.7	3
1057	Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18
1058	Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database. <i>Genes</i> , 2021, 12, 1350.	1.0	2
1059	Pathogenic Roles of CXCL10 in Experimental Autoimmune Prostatitis by Modulating Macrophage Chemotaxis and Cytokine Secretion. <i>Frontiers in Immunology</i> , 2021, 12, 706027.	2.2	19
1060	Predictive value of the monocyte-to-lymphocyte ratio in the diagnosis of prostate cancer. <i>Medicine (United States)</i> , 2021, 100, e27244.	0.4	14
1061	Characterization of fecal microbiome in biopsy positive prostate cancer patients. <i>BJUI Compass</i> , 2022, 3, 55-61.	0.7	9
1063	Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuitry and TLS-promoted genomic instability. <i>Biochemical Pharmacology</i> , 2021, 193, 114785.	2.0	6
1064	Increase in Akkermansiaceae in Gut Microbiota of Prostate Cancer-Bearing Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9626.	1.8	13
1065	Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor. <i>BioMed Research International</i> , 2021, 2021, 1-14.	0.9	9
1066	A case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk. <i>Meta Gene</i> , 2021, 30, 100962.	0.3	1
1067	Prostate cancer: Therapeutic prospect with herbal medicine. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100034.	1.7	13
1068	Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 31.	4.2	24
1069	Oxidative stress and prostate cancer. , 2021, , 15-26.		2

#	ARTICLE	IF	CITATIONS
1070	The prognostic value of the pretreatment serum albumin to globulin ratio for predicting adverse pathology in patients undergoing radical prostatectomy for prostate cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 545.	1.0	6
1071	EDCs and male urogenital cancers. <i>Advances in Pharmacology</i> , 2021, 92, 521-553.	1.2	5
1072	Links between Inflammation and Postoperative Cancer Recurrence. <i>Journal of Clinical Medicine</i> , 2021, 10, 228.	1.0	27
1073	Molecular detection of urogenital mollicutes in patients with invasive malignant prostate tumor. <i>Infectious Agents and Cancer</i> , 2021, 16, 6.	1.2	8
1074	A potential therapeutic strategy for prostatic disease by targeting the oral microbiome. <i>Medicinal Research Reviews</i> , 2021, 41, 1812-1834.	5.0	24
1075	Androgen-Dependent Oncogenic Activation of ETS Transcription Factors by Recurrent Gene Fusions in Prostate Cancer: Biological and Clinical Implications. , 2013, , 307-328.		7
1076	Cancer Stem Cells Provide New Insights into the Therapeutic Responses of Human Prostate Cancer. , 2013, , 51-75.		1
1077	Stem Cells in the Normal and Malignant Prostate. , 2013, , 3-41.		2
1078	Inflammation as a Target in Prostate Cancer. , 2010, , 375-386.		3
1079	Prostate Cancer Prevention by Short-Term Anti-androgens: The Rationale Behind Design of Pilot Studies. <i>Recent Results in Cancer Research</i> , 2009, 181, 195-205.	1.8	1
1080	The Protective Role of Zinc in Cancer: A Potential Chemopreventive Agent. , 2012, , 255-282.		2
1081	Antioxidant and Anti-inflammatory Action of Thymoquinone. , 2018, , 41-56.		3
1083	Epidemiology, Etiology, and Prevention of Prostate Cancer. , 2012, , 2704-2725.e7.		12
1085	Análisis del escenario microscópico de una biopsia prostática negativa como predictor del riesgo de cáncer de próstata. Una revisión sistemática. <i>Actas Urológicas Españolas</i> , 2019, 43, 337-347.	0.3	3
1086	Prostate calculi in cancer and BPH in a cohort of Korean men: presence of calculi did not correlate with cancer risk. <i>Asian Journal of Andrology</i> , 2010, 12, 215-220.	0.8	15
1087	Is XMRV a causal virus for prostate cancer?. <i>Asian Journal of Andrology</i> , 2011, 13, 698-701.	0.8	1
1088	Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis. <i>Asian Journal of Andrology</i> , 2012, 14, 715-719.	0.8	15
1089	Circumcision reduces prostate cancer risk. <i>Asian Journal of Andrology</i> , 2012, 14, 661-662.	0.8	16

#	ARTICLE	IF	CITATIONS
1090	MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness. <i>Oncogene</i> , 2020, 39, 3305-3321.	2.6	24
1091	Bacterial signatures and their inflammatory potentials associated with prostate cancer. <i>Apmis</i> , 2020, 128, 80-91.	0.9	26
1092	The evolving biology and treatment of prostate cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 2351-2361.	3.9	119
1093	An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. <i>Journal of Clinical Investigation</i> , 2009, 119, 2031-41.	3.9	44
1094	Incidental Finding of <i>Cryptococcus</i> on Prostate Biopsy for Prostate Adenocarcinoma Following Cardiac Transplant: Case Report and Review of the Literature. <i>American Journal of Case Reports</i> , 2017, 18, 1171-1180.	0.3	9
1095	Absence of nuclear receptors LXRs impairs immune response to androgen deprivation and leads to prostate neoplasia. <i>PLoS Biology</i> , 2020, 18, e3000948.	2.6	3
1096	Amyloid Formation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate. <i>PLoS ONE</i> , 2009, 4, e5562.	1.1	95
1097	Persistent Exposure to <i>Mycoplasma</i> Induces Malignant Transformation of Human Prostate Cells. <i>PLoS ONE</i> , 2009, 4, e6872.	1.1	134
1098	MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells. <i>PLoS ONE</i> , 2010, 5, e9427.	1.1	113
1099	ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer. <i>PLoS ONE</i> , 2010, 5, e10547.	1.1	122
1100	Suppressing an Anti-Inflammatory Cytokine Reveals a Strong Age-Dependent Survival Cost in Mice. <i>PLoS ONE</i> , 2010, 5, e12940.	1.1	14
1101	What Can Surrogate Tissues Tell Us about the Oxidative Stress Status of the Prostate? A Hypothesis-Generating In-Vivo Study. <i>PLoS ONE</i> , 2010, 5, e15880.	1.1	5
1102	MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors. <i>PLoS ONE</i> , 2011, 6, e17449.	1.1	77
1103	Blood Magnesium, and the Interaction with Calcium, on the Risk of High-Grade Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e18237.	1.1	53
1104	Evidence for a Pro-Proliferative Feedback Loop in Prostate Cancer: The Role of Epac1 and COX-2-Dependent Pathways. <i>PLoS ONE</i> , 2013, 8, e63150.	1.1	26
1105	Pathogenic Intestinal Bacteria Enhance Prostate Cancer Development via Systemic Activation of Immune Cells in Mice. <i>PLoS ONE</i> , 2013, 8, e73933.	1.1	53
1106	High Milk Consumption Does Not Affect Prostate Tumor Progression in Two Mouse Models of Benign and Neoplastic Lesions. <i>PLoS ONE</i> , 2015, 10, e0125423.	1.1	19
1107	LEDGF/p75 Overexpression Attenuates Oxidative Stress-Induced Necrosis and Upregulates the Oxidoreductase ERP57/PDIA3/GRP58 in Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0146549.	1.1	36

#	ARTICLE	IF	CITATIONS
1108	Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients. PLoS ONE, 2016, 11, e0147739.	1.1	13
1109	DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells. PLoS ONE, 2016, 11, e0166664.	1.1	13
1110	Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study. PLoS ONE, 2017, 12, e0168254.	1.1	9
1111	Frequency of Propionibacterium acnes Infection in Prostate Glands with Negative Biopsy Results Is an Independent Risk Factor for Prostate Cancer in Patients with Increased Serum PSA Titers. PLoS ONE, 2017, 12, e0169984.	1.1	19
1112	The mysterious relation between inflammation and prostate cancer. Infection International, 2017, 6, 8-12.	0.1	2
1113	DNA damage, oxidative stress, and inflammation in children with celiac disease. Genetics and Molecular Biology, 2020, 43, e20180390.	0.6	10
1114	Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma. Aging, 2020, 12, 25189-25206.	1.4	13
1115	Polyomavirus BK and prostate cancer: an unworthy scientific effort?. Oncoscience, 2014, 1, 296-303.	0.9	23
1116	Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. Oncotarget, 2016, 7, 71298-71308.	0.8	17
1117	Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. Oncotarget, 2017, 8, 24915-24931.	0.8	24
1118	Erectile dysfunction and the risk of prostate cancer. Oncotarget, 2017, 8, 52690-52698.	0.8	10
1119	Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget, 2017, 8, 60257-60269.	0.8	12
1120	Association of a common genetic variant in RNASEL and prostate cancer susceptibility. Oncotarget, 2017, 8, 75141-75150.	0.8	6
1121	Association of <i>Mycoplasma hominis</i> infection with prostate cancer. Oncotarget, 2011, 2, 289-297.	0.8	110
1122	Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget, 2018, 9, 34485-34494.	0.8	33
1123	The "Infectious" Nature of Human Prostate Cancer: A Cautionary Note. Oncotarget, 2011, 2, 281-283.	0.8	12
1124	Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer. Oncotarget, 2015, 6, 6459-6469.	0.8	11
1125	TLR9 signaling through NF- κ B/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget, 2015, 6, 17302-17313.	0.8	53

#	ARTICLE	IF	CITATIONS
1126	Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. <i>Oncotarget</i> , 2015, 6, 32169-32176.	0.8	53
1127	Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer. <i>Oncotarget</i> , 2016, 7, 18469-18484.	0.8	55
1128	Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer. <i>Oncotarget</i> , 2013, 4, 106-117.	0.8	75
1129	Prediction of <i>Mycoplasma hominis</i> proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology. <i>Oncotarget</i> , 2017, 8, 30830-30843.	0.8	36
1130	Association between gallbladder stone disease and prostate cancer: A nationwide population-based study. <i>Oncotarget</i> , 2016, 7, 64380-64389.	0.8	15
1131	IL-27/IL-27RA signaling may modulate inflammation and progression of benign prostatic hyperplasia via suppressing the LPS/TLR4 pathway. <i>Translational Cancer Research</i> , 2020, 9, 4618-4634.	0.4	2
1132	Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels. <i>Translational Cancer Research</i> , 2019, 8, 273-278.	0.4	5
1133	Resveratrol as an Adjuvant for Normal Tissues Protection and Tumor Sensitization. <i>Current Cancer Drug Targets</i> , 2020, 20, 130-145.	0.8	55
1134	HORMONAL IMPACT ON TUMOR GROWTH AND PROGRESSION. <i>Experimental Oncology</i> , 2015, 37, 162-172.	0.4	15
1135	Anti-cancer activities of <i>Ganoderma lucidum</i> : active ingredients and pathways. <i>Functional Foods in Health and Disease</i> , 2013, 3, 48.	0.3	68
1136	A comparison of the gene expression profiles and pathway network analyses after treatment of Prostate cancer cell lines with different <i>Ganoderma lucidum</i> based extracts. <i>Functional Foods in Health and Disease</i> , 2014, 4, 182.	0.3	4
1137	The Role of Chronic Inflammation in Prostate Carcinogenesis: A Follow-Up Study. <i>Annals of Urologic Oncology</i> , 2019, , 1-8.	0.0	3
1138	Inflammation in prostate cancer progression and therapeutic targeting. <i>Translational Andrology and Urology</i> , 2015, 4, 455-63.	0.6	55
1139	Estrogen receptor ($\hat{1}$ and $\hat{2}$) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. <i>Asian Journal of Andrology</i> , 2015, 17, 98.	0.8	14
1140	Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy. <i>Asian Journal of Andrology</i> , 2016, 18, 937.	0.8	17
1141	MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery. <i>Asian Journal of Andrology</i> , 2016, 18, 559.	0.8	43
1142	Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence. <i>Journal of Carcinogenesis</i> , 2011, 10, 27.	2.5	42
1143	Oncogenic activation of ERG: A predominant mechanism in prostate cancer. <i>Journal of Carcinogenesis</i> , 2011, 10, 37.	2.5	51

#	ARTICLE	IF	CITATIONS
1144	Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 910-918.	1.3	2
1145	Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression. <i>Journal of Cancer Science & Therapy</i> , 2010, 02, 89-94.	1.7	30
1146	Polycyclic Aromatic Hydrocarbons May Contribute for Prostate Cancer Progression. <i>Journal of Cancer Therapy</i> , 2013, 04, 37-46.	0.1	4
1147	Use of Non-steroidal Anti-inflammatory Drugs for Chemoprevention of Inflammation-induced Prostate Cancer. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2017, 14, 274-279.	0.6	1
1148	The effect of prostate tissue inflammation in benign prostatic hyperplasia on enhancer of zeste homolog 2 ribonucleic acid expression. <i>Annals of Saudi Medicine</i> , 2012, 32, 262-268.	0.5	5
1149	Association between systemic inflammation and serum prostatespecific antigen in a healthy Korean population. <i>Turkish Journal of Urology</i> , 2017, 43, 284-288.	1.3	5
1150	Original Paper Inflammatory changes in biopsy specimens from patients with suspected prostate cancer. <i>Central European Journal of Urology</i> , 2013, 66, 256-62.	0.2	8
1151	Molecular alterations associated with prostate cancer. <i>Central European Journal of Urology</i> , 2018, 71, 168-176.	0.2	6
1152	Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue. <i>International Neurourology Journal</i> , 2016, 20, 122-130.	0.5	12
1153	Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. <i>International Neurourology Journal</i> , 2015, 19, 74-84.	0.5	40
1154	Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2020, 11, 43-52.	0.9	12
1155	Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention. <i>South African Journal of Surgery</i> , 2012, 50, 127-30.	0.1	12
1156	Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6375-6379.	0.5	21
1157	Anticancer Activity of <i>Acanthopanax trifoliatum</i> (L) Merr Extracts is Associated with Inhibition of NF- κ B Activity and Decreased Erk1/2 and Akt Phosphorylation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 9341-9346.	0.5	15
1158	The Role of Microbial Factors in Prostate Cancer Development—An Up-to-Date Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4772.	1.0	10
1159	<sc>P2X4</sc> purinergic receptors offer a therapeutic target for aggressive prostate cancer. <i>Journal of Pathology</i> , 2022, 256, 149-163.	2.1	16
1160	The Genetic Basis of Cancer. , 2008, , 1-47.		0
1161	Cancer Immunology. , 2008, , 77-93.		1

#	ARTICLE	IF	CITATIONS
1162	Histopathology and Molecular Biology of Prostate Atrophy. , 2008 , , 1-15.		1
1163	Role of IL-6 in Regulating the Androgen Receptor. , 2009 , , 451-463.		1
1164	Stem Cell Niche Versus Cancer Stem Cell Niche – Differences and Similarities. , 2009 , , 223-233.		1
1165	The Epidemiology of Prostate Cancer. , 2010 , , 3-49.		0
1167	Prostate Cancer: A Pathological Perspective. , 2010 , , 87-120.		0
1168	Mechanisms of Carcinogenesis in Prostate Cancer. , 2010 , , 295-304.		0
1169	Lesioni precancerose e gray zone: aspetti clinici e pattern RM. , 2010 , , 79-85.		0
1170	Anti-inflammatory Activity of Calcitriol That Contributes to Its Therapeutic and Chemopreventive Effects in Prostate Cancer. , 2010 , , 1087-1104.		1
1171	The Pathology of Prostate Cancer. , 2010 , , 45-83.		2
1172	Pre-malignant Disease in the Prostate. , 2011 , , 467-491.		0
1173	Anti-inflammatory Activity of Calcitriol in Cancer. , 2011 , , 53-71.		2
1174	Prostate Inflammation and Prostate Cancer. , 2012 , , 103-115.		2
1175	Molecular Genetics and Cancer Biology. , 2012 , , 530-567.e16.		0
1176	Abstract IA25: Inflammation as the trigger of somatic epigenome defects in prostate cancer. Cancer Research, 2012, 72, IA25-IA25.	0.4	0
1178	The Association of Chronic Inflammation and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). , 0 , , .		1
1179	Physical Activity and Primary Cancer Prevention. , 2013 , , 83-106.		1
1181	Evaluating the Role of Curcum Powder as a Protective Factor against Bladder Cancer - An Experimental Study. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5287-5290.	0.5	1
1182	Molecular Determinants of Cancer-Related Inflammation. , 2013 , , 45-56.		0

#	ARTICLE	IF	CITATIONS
1183	The Role of Cholesterol in Prostate Cancer. , 2013, , 65-83.		0
1184	Epidemiology and Prevention of Prostate Cancer. , 2013, , 3-31.		0
1186	Epidemiology and Pathophysiology of LUTS/BPO. , 2014, , 21-31.		0
1188	Molecular Testing in Prostate Cancer. , 2014, , 277-300.		0
1189	Propionibacterium acnes and bacterial resistance. Surgical and Cosmetic Dermatology, 2015, 7, .	0.0	1
1190	Superiority of CCL11x IL-6 over PSA in Prostate Cancer Prediction and Detection in Egyptian Patients: First Preliminary Comparative Assessment. Journal of Cancer Prevention & Current Research, 2015, 2, .	0.1	0
1191	Prostata und Samenblasen. , 2016, , 139-194.		2
1192	Non Selective Inhibition of COX Activity Reversed Inflammation and Reactive Oxygen Radicals Mediated Prostate Cancer Risk and Decreased Disease Progression in Preclinical Model. Journal of Cancer Therapy, 2016, 07, 41-49.	0.1	0
1193	Role of C-Reactive Protein in Cancer. Energy Balance and Cancer, 2017, , 235-251.	0.2	0
1194	Chapter 1 Prostate Cancer: An Introduction. Traditional Herbal Medicines for Modern Times, 2016, , 1-16.	0.1	0
1195	Differentiation Diagnosis of Hypo-Intense T2 Area in Unilateral Peripheral Zone of Prostate Using Magnetic Resonance Spectroscopy (MRS): Prostate Carcinoma versus Prostatitis. Medical Science Monitor, 2017, 23, 3837-3843.	0.5	3
1196	The Role of Epigenetics. , 2017, , 75-107.		0
1197	Tissue accumulation effect of exogenous peptides â€“ the key to understanding the mechanisms of harmonization of immune homeostasis in patients with chronic bacterial prostatitis. Health of Man, 2017, .	0.1	0
1198	Metastatic Prostate Cancer. Molecular Pathology Library, 2018, , 279-295.	0.1	1
1199	A Taiwanese population-based study on the association between chronic tonsillitis and tonsil cancer. Oncotarget, 2018, 9, 7644-7650.	0.8	3
1200	Genitourinary Infectious Disease Pathology. , 2018, , 429-467.		0
1202	Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements. Advances in Experimental Medicine and Biology, 2019, 1210, 57-66.	0.8	3
1203	Novel Insight into Differential Gene Expression and Clinical Significance of Dopamine Receptors, COMT, and IL6 in BPH and Prostate Cancer. Current Molecular Medicine, 2019, 19, 605-619.	0.6	6

#	ARTICLE	IF	CITATIONS
1204	Prospects for the Use of Indole-3-carbinol in the Treatment of Benign Prostatic Hyperplasia. Health of Man, 2019, , 47-56.	0.1	0
1205	Influences and Complications. , 2020, , 217-266.		0
1206	Molecular Characterization of BK Polyomavirusâ€™ Large T Antigen Gene Sequences Detected in Prostate Cancer Tissues of Sudanese Patients. The Open Virology Journal, 2019, 13, 29-37.	1.8	1
1207	La proÛtata desde una perspectiva inmunològica. Medicina Y Laboratorio, 2020, 24, 13-35.	0.0	0
1209	Disposable free three port laparoscopic appendectomy â€™ low cost alternative for emergency. Gastroenterology & Hepatology (Bartlesville, Okla), 2020, 11, 94-98.	0.0	0
1210	Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 183-198.	0.8	1
1211	Relation of Serum Prostate-Specific Antigen with Histological Features and Grading of Prostate Adenocarcinoma in Prostatic Biopsies. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 193-197.	0.1	0
1213	Benign Prostatik Patolojilerde RegÃ¼latuvar T HÃ¼crelerinin (Treg) DeÄerlendirilmesi: Pilot ÄalÄma. KahramanmaraÅ SÃtÃn Ãmâniiversitesi TÃp FakÃltesi Dergisi, 0, , .	0.1	0
1214	Opportunities of Chronic Prostatitis Therapy with Flammulina velutipes. Health of Man, 2020, , .	0.1	0
1216	Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives. Current Drug Therapy, 2020, 15, 168-180.	0.2	0
1217	Metabolic imbalance and prostate cancer progression. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 248-71.	0.4	11
1218	Î±(V)Î²(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. American Journal of Translational Research (discontinued), 2012, 4, 165-74.	0.0	13
1220	Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. American Journal of Cancer Research, 2013, 3, 523-9.	1.4	46
1221	Interleukin-17 Induces Expression of Chemokines and Cytokines in Prostatic Epithelial Cells but Does Not Stimulate Cell Growth In Vitro. International Journal of Medical and Biological Frontiers, 2012, 18, 629-644.	0.2	9
1222	Infections and inflammation in prostate cancer. American Journal of Clinical and Experimental Urology, 2013, 1, 3-11.	0.4	42
1223	Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1Î². American Journal of Clinical and Experimental Urology, 2013, 1, 53-65.	0.4	10
1224	Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. American Journal of Clinical and Experimental Urology, 2014, 2, 231-8.	0.4	37
1225	Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer. American Journal of Cancer Research, 2015, 5, 2788-98.	1.4	19

#	ARTICLE	IF	CITATIONS
1227	Association between oral pathogens and prostate cancer: building the relationship. American Journal of Clinical and Experimental Urology, 2019, 7, 1-10.	0.4	7
1228	Mass cytometry reveals species-specific differences and a new level of complexity for immune cells in the prostate. American Journal of Clinical and Experimental Urology, 2019, 7, 281-296.	0.4	3
1229	Understanding and targeting prostate cancer cell heterogeneity and plasticity. Seminars in Cancer Biology, 2022, 82, 68-93.	4.3	31
1230	Identifying prognostic signatures in the microenvironment of prostate cancer. Translational Andrology and Urology, 2021, 10, 4206-4218.	0.6	3
1231	Overview of radiomics in prostate imaging and future directions. British Journal of Radiology, 2022, 95, 20210539.	1.0	7
1232	Osteopontin Deficiency Ameliorates Prostatic Fibrosis and Inflammation. International Journal of Molecular Sciences, 2021, 22, 12461.	1.8	9
1233	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	1.2	5
1234	Prostate cancer and human papillomavirus infection. Reviews in Medical Microbiology, 2020, Publish Ahead of Print, .	0.4	2
1235	Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene, 2022, , .	2.6	6
1236	Is clindamycin a potential treatment for prostatitis?. Apmis, 2022, 130, 197-205.	0.9	0
1237	The Role of Gut Microbiota and Metabolites in Obesity-Associated Chronic Gastrointestinal Disorders. Nutrients, 2022, 14, 624.	1.7	19
1238	Use of RNA-Seq and a Transgenic Mouse Model to Identify Genes Which May Contribute to Mutant p53-Driven Prostate Cancer Initiation. Biology, 2022, 11, 218.	1.3	1
1239	Exploiting Interdata Relationships in Prostate Cancer Proteomes: Clinical Significance of HO-1 Interactors. Antioxidants, 2022, 11, 290.	2.2	2
1240	The onset of age-related benign prostatic hyperplasia is concomitant with increased serum and prostatic expression of VEGF in rats: Potential role of VEGF as a marker for early prostatic alterations. Theriogenology, 2022, 183, 69-78.	0.9	1
1241	Health inequity drives disease biology to create disparities in prostate cancer outcomes. Journal of Clinical Investigation, 2022, 132, .	3.9	17
1242	Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis. Seminars in Cancer Biology, 2022, 86, 497-512.	4.3	21
1243	Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. Prostate, 2022, 82, 706-722.	1.2	10
1244	Expression of miR-24-1-5p in Tumor Tissue Influences Prostate Cancer Recurrence: The PROCA-life Study. Cancers, 2022, 14, 1142.	1.7	4

#	ARTICLE	IF	CITATIONS
1245	Propionibacterium acnes in urine and semen samples from men with urinary infection. <i>Archivio Italiano Di Urologia Andrologia</i> , 2022, 94, 62-64.	0.4	3
1246	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	1.7	10
1247	Inflammatory molecules facilitate the development of docetaxel-resistant prostate cancer cells in vitro and in vivo. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 837-849.	1.0	3
1248	Prostate Cancer Microbiome: A Narrative Review of What We Know So Far. <i>Current Clinical Microbiology Reports</i> , 0, , 1.	1.8	0
1249	Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity. <i>Pharmaceutics</i> , 2022, 14, 787.	2.0	16
1250	C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study. <i>International Journal of Cancer</i> , 2022, 151, 297-307.	2.3	21
1251	Mitochondria Dysfunction-Mediated Molecular Subtypes and Gene Prognostic Index for Prostate Cancer Patients Undergoing Radical Prostatectomy or Radiotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 858479.	1.3	16
1252	Proliferation of Mouse Prostate Cancer Cells Inflamed by <i>Trichomonas vaginalis</i> . <i>Korean Journal of Parasitology</i> , 2021, 59, 547-556.	0.5	5
1253	KLK3 in the Regulation of Angiogenesis—Tumorigenic or Not?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13545.	1.8	7
1254	<i>Cutibacterium acnes</i> Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer. <i>Microbiology Spectrum</i> , 2021, 9, e0149721.	1.2	10
1255	Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13605.	1.8	3
1256	Solid extraintestinal malignancies in patients with inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1956-1980.	0.8	5
1257	Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 991-998.	1.1	8
1265	Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	14
1266	Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. <i>Npj Precision Oncology</i> , 2022, 6, 31.	2.3	37
1267	Precision intervention for prostate cancer: Re-evaluating who is at risk. <i>Cancer Letters</i> , 2022, 538, 215709.	3.2	9
1268	The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers. <i>Journal of Clinical Medicine</i> , 2022, 11, 2925.	1.0	5
1269	The complex role of telocytes in female prostate tumorigenesis in a rodent model. <i>Cell Biology International</i> , 2022, 46, 1495-1509.	1.4	3

#	ARTICLE	IF	CITATIONS
1270	Pathological Roles of Reactive Oxygen Species in Male Reproduction. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 41-62.	0.8	5
1271	Usefulness of Collaborative Work in the Evaluation of Prostate Cancer from MRI. <i>Clinics and Practice</i> , 2022, 12, 350-362.	0.6	2
1274	The Effect of Oncogene Proteins of Human Papillomaviruses on Apoptosis Pathways in Prostate Cancer. <i>Oncologie</i> , 2022, 24, 227-245.	0.2	5
1275	Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
1276	Cervical Cancer Outcome and Tumor-Associated Macrophages: Research Evidence. <i>Immuno</i> , 2022, 2, 460-468.	0.6	2
1277	Clinical significance of distally located periurethral calcification in patients with lower urinary tract symptoms of benign prostate hyperplasia. <i>Asian Journal of Andrology</i> , 2022, .	0.8	0
1278	Association of Cytokine Gene Polymorphisms with Prostate Cancer Risk from a Study in Central China. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-11.	0.4	3
1279	Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer. <i>Drug Resistance Updates</i> , 2022, 64, 100865.	6.5	4
1280	New generation biomarkers for the detection of prostate cancer. <i>Biosensors and Bioelectronics: X</i> , 2022, 12, 100250.	0.9	2
1281	Investigating Causal Relations between Genetic-Related Intermediate Endophenotype and Risk of Chronic Prostatitis: Mendelian Randomization Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-10.	1.9	1
1282	Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment. <i>Cancers</i> , 2022, 14, 4412.	1.7	4
1283	SNAT2 is responsible for hyperosmotic induced sarcosine and glycine uptake in human prostate PC-3 cells. <i>Pflugers Archiv European Journal of Physiology</i> , 2022, 474, 1249-1262.	1.3	3
1284	Sleep Patterns and Risk of Prostate Cancer: A Population-Based Case Control Study in France (EPICAP). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2070-2078.	1.1	3
1286	Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. <i>Molecules</i> , 2022, 27, 5730.	1.7	133
1287	The regulatory role of PDE4B in the progression of inflammatory function study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1288	Correlation Between Long-Term Acetylsalicylic Acid Use and Prostate Cancer Screening with PSA. Should We Reduce the PSA Cut-off for Patients in Chronic Therapy? A Multicenter Study. <i>Research and Reports in Urology</i> , 0, Volume 14, 369-377.	0.6	0
1289	<i>Trichomonas vaginalis</i> as risk factor for prostatic diseases. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
1290	Integrated analysis to identify the AC005154.6/hsa-miR-29c-3p/CCNL2 axis as a novel prognostic biomarker associated with immune infiltration in prostate cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1

#	ARTICLE	IF	CITATIONS
1292	The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 965-974.	2.7	0
1293	“Stromal cells in prostate cancer pathobiology: friends or foes?” <i>British Journal of Cancer</i> , 2023, 128, 930-939.	2.9	9
1295	UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	11
1296	Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	8
1297	Tumor-associated macrophages in prostate cancer: role in progression and therapy. , 2023, , 153-180.		0
1298	Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. <i>Oncology Research</i> , 2022, 30, 137-155.	0.6	5
1300	Megakaryocyte-Derived IL-8 Acts as a Paracrine Factor for Prostate Cancer Aggressiveness through CXCR2 Activation and Antagonistic AR Downregulation. <i>Biomolecules and Therapeutics</i> , 2023, 31, 210-218.	1.1	1
1302	A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia. <i>Journal of Clinical Medicine</i> , 2023, 12, 1821.	1.0	3
1303	Inflammatory response to <i>Trichomonas vaginalis</i> in the pathogenesis of prostatitis and benign prostatic hyperplasia. , 2023, 61, 2-14.		2
1304	Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. <i>Dermatology and Therapy</i> , 2023, 13, 867-889.	1.4	2
1305	Identification of Essential Genes and Drug Discovery in Bladder Cancer and Inflammatory Bowel Disease via Text Mining and Bioinformatics Analysis. <i>Current Computer-Aided Drug Design</i> , 2024, 20, 359-366.	0.8	1
1319	The potential role of the microbiota in prostate cancer pathogenesis and treatment. <i>Nature Reviews Urology</i> , 2023, 20, 706-718.	1.9	4
1321	Multifactorial considerations of human health and public health in oncology. , 2023, , 573-580.		0
1335	The Interleukin-8 Pathway in Cancer. , 2023, , 165-190.		0
1339	Vitamin D, inflammation, and cancer. , 2024, , 797-824.		0
1352	Basic Insights into Tumor Microenvironment in Prostate Cancer. , 2024, , 43-71.		0